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ABBREVIATIONS
Ae amount excreted in urine
AhR aryl hydrocarbon receptor
ANOVA analysis of variance
Arnt AhR nuclear translocator
AUC area under the concentration-time curve
AUEC area under the effect-time curve
BCRP breast cancer resistance protein
BMI body mass index
CAR constitutive androstane receptor
Clrenal renal clearance
Cmax peak concentration
CoA coenzyme A
COX cyclooxygenase
COMT catechol O-methyltransferase
CV coefficient of variation
CYP cytochrome P450
DNA deoxyribonucleic acid
DSST Digit Symbol Substitution Test
EDTA ethylenediaminetetraacetic acid
FMO flavin-containing monooxygenase
GABA ?-aminobutyric acid
GST glutathione transferase
HIV human immunodeficiency virus
HLM human liver microsomes
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A
HPLC high-performance liquid chromatography
IC50 inhibitor concentration producing 50% decrease in activity
ke elimination rate constant
kf apparent formation rate constant
Ki inhibition constant
Km Michaelis-Menten constant
LC-MS-MS liquid chromatography-tandem mass spectrometry
MAO monoamine oxidase
mRNA messenger ribonucleic acid
MRP multidrug resistance-associated protein
NADPH nicotinamide adenine dinucleotide phosphate
NAT arylamine N-acetyltransferase
NSAID non-steroidal anti-inflammatory drug
OAT organic anion transporter
OATP organic anion transporting polypeptide
OCT organic cation transporter
OCTN organic cation/carnitine transporter
PAH polycyclic aromatic hydrocarbon
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PCR polymerase chain reaction
PEPT peptide transporter
P-gp P-glycoprotein (also MDR1)
pKa acid dissociation constant
PPAR peroxisome proliferator activated receptor
PXR pregnane X receptor
rhCYP recombinant human CYP
RXR retinoid X receptor
SD standard deviation
SE standard error
SNP single nucleotide polymorphism
SSRI selective serotonin reuptake inhibitor
SULT sulfotransferase
t½ elimination half-life
tmax time to peak concentration
TPMT thiopurine methyltransferase
UGT UDP-glucuronosyltransferase
VAS visual analogue scale
Vmax maximum reaction velocity
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ABSTRACT
Background and aims
Cytochrome P450 (CYP) 2C8 is involved in the metabolism of several clinically used drugs,
including paclitaxel, repaglinide and rosiglitazone. Drug interactions caused by inhibition or
induction of CYP2C8 can cause considerable variation in the effective exposure to its
substrates. The aim of this work was to investigate the effect of model inhibitors of CYP2C8
on the pharmacokinetics of loperamide, zopiclone, ibuprofen and pioglitazone, in order to
characterise the role of CYP2C8 in their metabolism. Gemfibrozil and trimethoprim were
used as model inhibitors of CYP2C8. In addition, the effect of the CYP2C8*3 allele on the
pharmacokinetics of pioglitazone was investigated. Finally, the effect of dosing interval
between gemfibrozil and repaglinide was studied in relation to the gemfibrozil-repaglinide
interaction.
Methods
Studies I to V were randomised crossover studies with 2 to 5 phases. 10 to 16 healthy
volunteers participated in each study. Pre-treatment with a clinically relevant dose of
inhibitor (gemfibrozil, itraconazole or trimethoprim) was followed by a single oral dose of
the study drug (loperamide, zopiclone, ibuprofen, pioglitazone or repaglinide). Thereafter,
blood and urine samples were collected for the determination of drug concentrations. The
pharmacodynamics of loperamide and zopiclone were assessed by psychomotor tests and
subjective evaluations, and that of repaglinide by blood glucose measurements. Additionally,
the metabolism of zopiclone and pioglitazone was studied in vitro in studies II and IV.
Results
Gemfibrozil, itraconazole and their combination raised the area under the concentration-time
curve (AUC) of loperamide 2.2- (P <  0.05),  3.8-  (P < 0.001) and 12.6-fold (P < 0.001),
respectively, compared to placebo. Gemfibrozil had no effect on the pharmacokinetics of
parent zopiclone. On the other hand, gemfibrozil raised the AUC of R-ibuprofen by 34% (P
< 0.001) and increased its elimination half-life (t½) from 2.9 to 4.5 hours (P < 0.001), with
only minor effects on the S-enantiomer of ibuprofen. Trimethoprim raised the AUC of
pioglitazone by 42% (P < 0.001) and prolonged its dominant t½ from 3.9 to 5.1 hours (P <
0.001), but had no effect on its peak plasma concentration (Cmax). The CYP2C8*3 allele was
associated with a decreased AUC of pioglitazone compared to the subjects with the reference
genotype (CYP2C8*1/*1),  and  after  correction  for  weight,  this  difference  was  statistically
significant  (P < 0.05). The gemfibrozil-repaglinide interaction persisted up to a 12 hour
dosing interval between gemfibrozil and repaglinide. Gemfibrozil ingested simultaneously
with or 3, 6, or 12 hours before repaglinide increased repaglinide AUC0-? 7.0-, 6.5-, 6.2- and
5.0-fold, respectively (P < 0.001), and the Cmax of repaglinide increased about two-fold in all
gemfibrozil phases (P < 0.001), compared to control. During repaglinide administration, the
mean blood glucose concentration from 0 to 9 hours decreased in each of the gemfibrozil
phases, compared to control (P < 0.005), whereas the pharmacodynamics of loperamide and
zopiclone were not affected by the pre-treatment drugs.
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In vitro, zopiclone (500 nM) elimination was not affected by the CYP2C8 inhibitors
montelukast and gemfibrozil, but the CYP3A4 inhibitors itraconazole and ketoconazole
markedly inhibited its elimination. Pioglitazone metabolite M-IV formation was inhibited by
trimethoprim in pooled human liver microsomes (HLM) and recombinant human CYP2C8
(rhCYP2C8).  At  clinically  relevant  concentrations  of  pioglitazone,  CYP2C8  was
predominantly responsible for M-IV formation, whereas at higher concentrations the role of
CYP3A4 increased.
Conclusions
These  studies  clarify  the  role  of  CYP2C8  in  the  metabolism  of  several  drugs.  The
concentrations of loperamide and R-ibuprofen were found to be increased by the CYP2C8
inhibitor gemfibrozil, indicating that CYP2C8 participates in the metabolism of these drugs
in vivo. On the other hand, the metabolism of zopiclone at clinically relevant concentrations
was not affected in vivo or in vitro by CYP2C8 inhibition. Trimethoprim moderately raised
the plasma concentrations of pioglitazone by inhibiting its CYP2C8-mediated
biotransformation. In addition, the CYP2C8*3 allele was associated with increased metabolic
clearance of pioglitazone in vivo, which is in line with the results of pharmacogenetic studies
on repaglinide and rosiglitazone. The inhibitory effect of gemfibrozil on CYP2C8 persists at
least 12 hours, strongly suggesting that the main mechanism of the gemfibrozil-repaglinide
interaction is irreversible mechanism-based inhibition of CYP2C8.
INTRODUCTION
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INTRODUCTION
Drug interactions can cause considerable variation in drug responses and increase the risk of
adverse drug reactions. Many drug-drug interactions occur during metabolic processing, as
most drugs need to be metabolised in order to be eliminated from the body. Cytochrome
P450 (CYP) enzymes are of major importance in the biotransformation of a great number of
drugs. The liver is the main organ of CYP-mediated metabolism (Meyer 1996). However,
CYP enzymes are expressed in other tissues as well, and extrahepatic metabolism can be
significant for many drugs (Krishna and Klotz 1994).
Drugs that inhibit CYP enzymes can affect the elimination of other drugs, increasing their
plasma concentrations, and leading to enhanced effects or increased toxicity. In the case of
prodrugs, which are activated by CYP-mediated metabolism, inhibition can lead to lower
concentrations of the active compound and lack of efficacy (Lin and Lu 1998).
The importance of CYP2C8 in drug metabolism has only recently been recognised. To date,
CYP2C8 has been found to play a major role in the metabolism of several drugs, including
paclitaxel, cerivastatin, repaglinide, rosiglitazone and pioglitazone (Rahman et al. 1994,
Wang et al. 2002b, Bidstrup et al. 2003, Baldwin et al. 1999, Jaakkola et al. 2006c). At first,
however, the importance of CYP2C8 was greatly underestimated, in many cases based on in
vitro studies, and only later drug interaction studies revealed the importance of CYP2C8 in
the metabolism of drugs such as cerivastatin, repaglinide and pioglitazone (Backman et al.
2002, Niemi et al. 2003b, Jaakkola et al. 2005).
Many drugs, including loperamide, zopiclone and ibuprofen, have been reported to be
metabolised by CYP2C8 in vitro (Kim et al. 2004, Becquemont et al. 1999, Hamman et al.
1997). However, no in vivo data has been available on the role of CYP2C8 in the metabolism
of loperamide and zopiclone, and pharmacogenetic studies have provided only indirect
evidence of the participation of CYP2C8 in the metabolism of ibuprofen (Totah and Rettie
2005). Pioglitazone is metabolised by CYP2C8 both in vitro and in vivo, but the effect of the
model CYP2C8 inhibitor trimethoprim on the pharmacokinetics of pioglitazone has not been
documented in vivo. In addition, several allelic variants of the CYP2C8 gene have been
recognised, but the evidence regarding the effect of the most common polymorphism leading
to amino acid changes in Caucasians, CYP2C8*3, has been somewhat contradictory. As this
polymorphism has been reported to cause both increased and decreased metabolic activity, it
has not been clear how it affects the pharmacokinetics of different substrates of CYP2C8,
e.g. pioglitazone.
Although the lipid-lowering drug gemfibrozil is only a weak inhibitor of CYP2C8 in vitro, it
greatly increases the plasma concentrations of several drugs metabolised by CYP2C8. The in
vivo inhibition of CYP2C8 by gemfibrozil has been proposed to be mediated by its
glucuronide metabolite, which is a mechanism-based inhibitor of CYP2C8 (Ogilvie et al.
2006). However, the clinical relevance of the irreversible mechanism-based inhibition that
has been observed in vitro with gemfibrozil glucuronide is not known. In addition,
gemfibrozil can also inhibit other CYP enzymes and drug transporters, and the contribution
of the different mechanisms to drug interactions caused by gemfibrozil is somewhat
uncertain.
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The purpose of this work was to investigate CYP2C8-mediated drug interactions both in
vitro and in vivo. The effects of gemfibrozil on the pharmacokinetics of loperamide,
zopiclone and ibuprofen, and the effect of trimethoprim on pioglitazone were studied. In
addition, this work investigated the impact of the CYP2C8*3 allele on pioglitazone
pharmacokinetics and the effect of dosing interval on the gemfibrozil-repaglinide interaction.
REVIEW OF THE LITERATURE
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REVIEW OF THE LITERATURE
1. Drug-metabolising enzymes and transporters
1.1. Principles of drug metabolism
Drugs are eliminated from the body via metabolism and excretion. Most drugs are lipophilic
compounds, and thus in order to be excreted they must be biotransformed into more water
soluble forms (Meyer 1996). The liver is the major organ of drug metabolism, but other
organs, e.g. gastrointestinal tract, kidneys, lung and skin, can also contribute to drug
metabolism (Krishna and Klotz 1994). When a drug is administered orally, it already begins
to be biotransformed in the gastrointestinal tract by enterocytes, and in the liver after passing
through the portal vein, before it enters systemic circulation. This phenomenon is called
first-pass metabolism, and it can considerably decrease the oral bioavailability of many
drugs (Shen et al. 1997).
Drug biotransformation has been traditionally classified into phase I functionalisation and
phase II conjugation reactions. The phase I enzymes insert a functional group on their
substrate, and the phase II enzymes conjugate their substrates with endogenous molecules.
Most phase I metabolism reactions are catalysed by CYP enzymes in the endoplasmic
reticulum. The resulting metabolites are usually inactive or less active than the parent drug.
However, there are also examples of toxic metabolites, and metabolism-activated drugs
(prodrugs) (Meyer 1996). The phase II enzymes, including for example UDP-
glucuronosyltransferases (UGT), sulfotransferases (SULT) and glutathione transferases
(GST), in general facilitate the excretion of their substrates by biotransforming them into
more water-soluble forms, and they are located in both cytoplasm and endoplasmic
reticulum (Cribb et al. 2005). Despite the nomenclature, phase II metabolism can occur on
some unchanged drugs and phase I enzymes can also metabolise conjugated drugs (Josephy
et al. 2005).
The inter-individual variability in drug disposition is high, and can be affected by
environmental, genetic and disease determinants. A major part of the individual differences
in drug response can be caused by drug interactions, including inhibition and induction, and
genetic variability in drug-metabolising enzymes and transporters. (Wilkinson 2005, Ho and
Kim 2005).
1.2. CYP enzymes and their nomenclature
The cytochrome P450 enzymes (CYP enzymes) are a superfamily of heme-containing
monooxygenases (Wrighton and Stevens 1992). The name originates from their distinct peak
absorption wavelength (450 nm) when the reduced form of the enzyme has bound carbon
monoxide (Omura and Sato 1962).
The most common and well-known type of reaction catalysed by CYP enzymes is insertion
of oxygen onto the substrate. The first step in the catalytical cycle is the binding of the
substrate to the apoprotein moiety of the ferric (Fe3+) haemoprotein. In the second step, this
complex undergoes one-electron reduction to the ferrous (Fe2+) state by accepting an
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electron from nicotinamide adenine dinucleotide phosphate (NADPH) via the NADPH
cytochrome P450 reductase. The third step is the binding of molecular oxygen to the ferrous
ion of the complex, followed by a second one-electron reduction. After this, one atom of the
oxygen is reduced to water, and the other atom is inserted into the substrate. Finally, the
complex dissociates to the product (oxidised metabolite) and free enzyme to allow the
catalytical cycle to be repeated (Sheweita 2000, Werck-Reichhart and Feyereisen 2000). The
reactions catalysed by CYP enzymes include hydroxylation, epoxidation, dealkylation,
dehalogenation, N- and S-oxidation, as well as oxidative deamination (Gibson and Skett
2001, Parkinson 2001).
Cytochrome P450s are named by a number indicating the gene family with >40% amino
acid sequence identity (e.g. CYP3), a letter indicating the subfamily with >55% amino acid
sequence identity (e.g. CYP3A), and a number for the gene (e.g. CYP3A4) (Nebert and
Russell 2002). The names of CYP genes are presented in italics (e.g. CYP2C8), and the
specific alleles are indicated with an asterisk followed by an Arabic numeral (e.g.
CYP2C8*3). The name of the protein encoded by the gene is non-italicised, with a period
between the gene product and number (e.g. CYP2C8.3). The reference sequence (i.e. *1) is
the first allele sequenced, and thus not necessarily the most common one in all ethnic
populations (Ingelman-Sundberg et al. 2000). An up-to-date listing of the human CYP alleles
can be found at http://www.cypalleles.ki.se.
In humans, 57 CYP enzymes have been identified. Of the 18 CYP families, the CYP1, CYP2
and CYP3 families predominantly participate in the metabolism of xenobiotics, whereas the
other CYP families have mainly endogenous roles (Nebert and Russell 2002, Lewis 2004).
1.3. CYP2C8
The importance of CYP2C8 in drug metabolism has become recognised only recently partly
due to a lack of diagnostic inhibitors (Totah and Rettie 2005). CYP2C8 accounts for about
6%  of  the  total  liver  CYP  content  (Rowland-Yeo  et  al.  2003).  In  addition  to  hepatocytes,
CYP2C8 protein has been detected in salivary ducts, intestine, kidney and adrenal cortical
cells (Enayetallah et al. 2004). However, the protein expression of CYP2C8 in the intestine
is low (Läpple et al. 2003). The crystal structure of the CYP2C8 enzyme has been
determined to 2.7 Å resolution (Schoch et al. 2004). It has a relatively large active site cavity
(1438 Å3), similar in size to that of CYP3A4 (1386 Å3), but the shapes of the cavities differ
considerably (Yano et al. 2004). This provides an explanation for why CYP2C8 and
CYP3A4 share many substrates, but often catalyse the formation of different metabolites.
1.3.1. Substrates
CYP2C8 plays a major role in the metabolism of several drugs, including amodiaquine,
cerivastatin, paclitaxel, pioglitazone, repaglinide and rosiglitazone (Table 1) (Li et al. 2002,
Wang et al. 2002b, Rahman et al. 1994, Jaakkola et al. 2006c, Bidstrup et al. 2003, Kajosaari
et al. 2005a, Baldwin et al. 1999). In addition, certain endogenous agents such as arachidonic
acid and retinoic acid can be metabolised by CYP2C8 (Rifkind et al. 1995, Nadin and
Murray 1999). Notably, CYP2C8 shares a number of substrates with CYP3A4, but less with
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other CYPs. In addition, CYP2C8 has been shown to metabolise some glucuronide
conjugates of drugs, e.g. diclofenac acyl glucuronide (Kumar et al. 2002).
Table 1. Examples of CYP2C8 substrates, inhibitors and inducers.
Substrates Reference Inhibitors Reference
Amiodarone (3A4) Ohyama et al. 2000 Clotrimazole Ong et al. 2000
Amodiaquine Li et al. 2002 Gemfibrozil Wang et al. 2002b
Ketoconazole Ong et al. 2000Arachidonic acid (1A2,
2C9, 2E1) Rifkind et al. 1995
Buprenorfin (3A4) Picard et al. 2005
Mometasone
 furoate
Walsky et al. 2005a
Carbamazepine (3A4) Kerr et al. 1994 Montelukast Walsky et al. 2005b
Cerivastatin (3A4) Wang et al. 2002b Trimethoprim Wen et al. 2002
Chloroquine (3A4) Projean et al. 2003a Quercetin Rahman et al. 1994
Diclofenac (2C9) Bort et al. 1999 Zafirlukast Walsky et al. 2005a
Ibuprofen (2C9) Hamman et al. 1997
Loperamide (3A4) Kim et al. 2004 Inducers
Methadone (3A4, 2D6) Wang and DeVane 2003 Dexamethasone
Morphine (3A4) Projean et al. 2003b Phenobarbital
Paclitaxel (3A4) Rahman et al. 1994 Rifampicin
Gerbal-Chaloin et al.
2001
Pioglitazone (3A4) Jaakkola et al. 2006c
Repaglinide (3A4) Bidstrup et al. 2003
Retinoic acid (2C9) Nadin and Murray 1999
Rosiglitazone (2C9) Baldwin et al. 1999
Simvastatin acid (3A4) Prueksaritanont et al. 2003
Troglitazone (3A4) Yamazaki et al. 1999
Zopiclone (3A4) Becquemont et al. 1999
Other CYP enzymes participating in the biotransformation of the substrates are given in parenthesis.
1.3.2. Inhibitors and inducers
The inhibitory potential of a large number of xenobiotics to CYP2C8 has been characterised
in vitro (Table 1) (Ong et al. 2000, Walsky et al. 2005a, Tornio et al. 2005). Initially,
quercetin was used as a diagnostic in vitro inhibitor despite its low selectivity. In vitro,
trimethoprim  and  especially  montelukast  are  selective  inhibitors  of  CYP2C8  (Wen  et  al.
2002, Walsky et al. 2005b). In vivo, trimethoprim is a moderately potent inhibitor of
CYP2C8 (Niemi et al. 2004b, Niemi et al. 2004a). However, montelukast has been found to
have no effect on the CYP2C8 substrates repaglinide and pioglitazone in vivo, probably due
to the extensive plasma protein binding of montelukast (Kajosaari et al. 2006b, Jaakkola et
al. 2006b). Gemfibrozil is a strong in vivo inhibitor of CYP2C8 (Backman et al. 2002, Niemi
et al. 2003a, Niemi et al. 2003b), which seems to be explained to a great extent by its 1-O-?-
glucuronide metabolite, which is a mechanism-based inhibitor of CYP2C8 (Shitara et al.
2004, Ogilvie et al. 2006). Several other drugs, such as clotrimazole and mometasone
furoate, are potent inhibitors of CYP2C8 in vitro (Walsky et al. 2005a). They are, however,
topically applied drugs and thus unlikely to cause clinically relevant drug interactions, since
their systemic concentrations are low. In addition, the CYP3A4 inhibitor ketoconazole has
been shown to inhibit CYP2C8, and the inhibitory effect is observed at a concentration of 1
µM in vitro (Ong et al. 2000). In vivo, CYP2C8 is induced by rifampicin, and in vitro
evidence suggests inducibility by phenobarbital and dexamethasone (Niemi et al. 2000,
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Gerbal-Chaloin et al. 2001). In addition, CYP2C8 has been reported to be induced in human
hepatocytes by fibrates, including fenofibric acid, clofibric acid and gemfibrozil
(Prueksaritanont et al. 2005).
1.3.3. Pharmacogenetics
The CYP2C8 gene spans a 31 kilobase region with 9 exons (Klose et al. 1999). To date,
several nucleotide sequence variations have been identified in CYP2C8. CYP2C8*3
(c.416G>A, p.Arg139Lys and c.1196A>G, p.Lys399Arg) is the most frequent variant allele
changing  the  amino  acid  sequence  of  CYP2C8 in  the  Caucasian  population,  with  an  allele
frequency of about 10-20%. On the other hand, the most common amino acid changing
polymorphism in black populations is CYP2C8*2 (c.805A>T, p.Ile269Phe), but it is very
rare in Caucasians. The CYP2C8*4 (c.792C>G, p.Ile264Met) allele is present, at least in
Caucasian populations, with an allele frequency of about 8% (Totah and Rettie 2005). In
vitro studies have suggested that CYP2C8.3 has reduced activity for metabolising paclitaxel,
arachidonic acid and amodiaquine, but amidarone N-deethylation was not affected by this
polymorphism (Table 2) (Dai et al. 2001, Soyama et al. 2001, Bahadur et al. 2002, Parikh et
al. 2007, Soyama et al. 2002). In vivo, the CYP2C8*3 allele  has  been  associated  with
decreased plasma concentrations of repaglinide and rosiglitazone (Niemi et al. 2003c,
Kirchheiner et al. 2006). However, no effect was evident on the pharmacokinetics of
paclitaxel in relation to the CYP2C8 genotype (Henningsson et al. 2005). On the other hand,
the clearance of ibuprofen was markedly decreased in carriers of the CYP2C8*3 allele
(García-Martín et al. 2004). Thus, the general in vivo effect  of  the CYP2C8*3 allele is
unclear. Additionally, there is a strong linkage disequilibrium between CYP2C8*3 and
CYP2C9*2 (c.430C>T, p.Arg144Cys) variant alleles, and more than 95% of individuals with
the CYP2C8*3 allele have also been reported to be carriers of the CYP2C9*2 allele (Yasar et
al. 2002). Recently, two novel haplotypes, characterised by non-coding single nucleotide
polymorphisms (SNP) with the dbSNP identifiers rs7909236 and rs1113129/rs3216029,
have been identified with frequencies of about 20% in Caucasians (Rodríguez-Antona et al.
2007). The former was associated with increased activity for metabolising paclitaxel in vitro
and repaglinide in vivo and the latter with reduced activity both in vitro and in vivo. Due to
the role of CYP2C8 in the biosynthesis of vasoactive substances from arachidonic acid, the
CYP2C8 genotype has been investigated as a risk factor for cardiovascular morbidity, but
conclusive evidence for this is still lacking (Yasar et al. 2003, Lee et al. 2007).
Table 2. CYP2C8.3 activity toward substrates compared to CYP2C8.1.
Substrate In vitro In vivo Reference
Amiodarone ? Soyama et al. 2002
Amodiaquine ? Parikh et al. 2007
Arachidonic
acid ? Dai et al. 2001
Ibuprofen ? García-Martín et al. 2004, Martínez et al. 2005
Paclitaxel ? ? Dai et al. 2001, Henningsson et al. 2005
Repaglinide ? Niemi et al. 2003c, Niemi et al. 2005b
Rosiglitazone ? Kirchheiner et al. 2006
? increased activity, ? decreased activity, ? no change in activity.
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1.4. Other CYP enzymes
1.4.1. CYP1A subfamily
The CYP1A subfamily has two members: CYP1A1 and CYP1A2. CYP1A1 is mostly
extrahepatic, and participates in the metabolism of endogenous substrates (Nebert and
Russell 2002). On the other hand, CYP1A2 is mainly found in the liver, and accounts for 10-
20% of the total CYP content in the liver (Rowland-Yeo et al. 2003, Klein et al. 2006).
CYP1A2 metabolises several drugs, such as caffeine, theophylline, clozapine and tizanidine
(Table 3) (Bertilsson et al. 1994, Pelkonen et al. 1998, Granfors et al. 2004a). CYP1A2
inhibitors include ciprofloxacin and fluvoxamine (Fuhr et al. 1992, Brøsen et al. 1993).
Polyaromatic hydrocarbons (PAH), found for instance in cigarette smoke and grilled food,
can induce the expression of CYP1A enzymes via the aryl hydrocarbon receptor (AhR)
(Nebert and Russell 2002).
1.4.2. CYP2A6
CYP2A6 represents 1-10% of the total liver CYP content (Rowland-Yeo et al. 2003, Klein et
al. 2006), and is involved in the metabolism of at least nicotine and coumarin. Methoxsalen
and pilocarpine are potent inhibitors of CYP2A6 and it seems to be induced by phenobarbital
(Kimonen et al. 1995, Pelkonen et al. 2000). The CYP2A6 enzyme is also polymorphic, and
the CYP2A6 genotype affecting nicotine metabolism can have an influence on smoking
habits (Malaiyandi et al. 2005).
1.4.3. CYP2B6
CYP2B6 constitutes on average only about 3% of the total hepatic CYP content, but the
inter-individual variability in its expression is very high (Rowland-Yeo et al. 2003), probably
due to both genetic polymorphisms and inductive effects of various xenobiotics (Wang and
Negishi 2003, Zanger et al. 2007). Until recently, it had been regarded to be of minor
importance in drug metabolism. However, CYP2B6 has been found to play a major role in
the metabolism of drugs such as bupropion, propofol and efavirenz (Table 3). Thiotepa,
ticlopidine and clopidogrel are potent inhibitors of CYP2B6 (Turpeinen et al. 2006).
CYP2B6 is also highly polymorphic, with functional consequences, e.g. altered efavirenz
concentrations in vivo (Zanger et al. 2007).
1.4.4. CYP2C subfamily
In addition to CYP2C8, there are three other members of the CYP2C subfamily: CYP2C9,
CYP2C18 and CYP2C19. These enzymes are of clinical importance, with the exception of
CYP2C18, which has not been found to be expressed in any tissue (Table 3). The other
CYP2C  enzymes  are  expressed  mainly  in  the  liver,  but  also  in  the  intestine  (Obach  et  al.
2001, Läpple et al. 2003). All of the CYP2C enzymes are genetically polymorphic (Daly
2003).
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CYP2C9 is the most abundant CYP2C isoform in both the liver (about 17% of the total liver
CYP content) and intestine (Läpple et al. 2003). It metabolises a number of drugs, including
S-warfarin, tolbutamide and several non-steroidal anti-inflammatory drugs (NSAIDs).
Sulphaphenazole, amiodarone and several azole antifungals inhibit CYP2C9, and it is
induced by rifampicin and barbiturates (Miners and Birkett 1998). The CYP2C9
polymorphisms have clinical implications e.g. in warfarin treatment (Aithal et al. 1999,
Wadelius and Pirmohamed 2007).
CYP2C19, constituting about 3% of the total hepatic CYP content (Rowland-Yeo et al.
2003), metabolises proton pump inhibitors, diazepam, citalopram and tricyclic
antidepressants. A prototypical substrate for CYP2C19 is S-mephenytoin, and omeprazole is
its inhibitor both in vitro and in vivo, but is rather unselective. Up to 6% of Caucasians are
poor  metabolisers  of  substrates  of  CYP2C19  (Desta  et  al.  2002).  The CYP2C19 genotype
can affect, for example, the efficacy of proton pump inhibitor treatment (Furuta et al. 2004).
1.4.5. CYP2D6
The relative CYP2D6 content in the liver is only about 4%, but it has been estimated to be
involved in the metabolism of up to 25% of all drugs (Zanger et al. 2001, Ingelman-
Sundberg 2005). Most CYP2D6 substrates are distinct in that they have a basic nitrogen
located close to their site of oxidation (Zanger et al. 2004). Its substrates include for example
several beta-blockers, tricyclic antidepressants, selective serotonin reuptake inhibitors
(SSRIs), antipsychotics and other drugs such as codeine and dextromethorphan (Table 3)
(Pelkonen et al. 1998). Many drugs, including quinidine, flecainide, paroxetine,
moclobemide and fluoxetine, inhibit CYP2D6 (Zanger et al. 2004). In contrast to other drug-
metabolising CYP enzymes, CYP2D6 is not known to be inducible (Ingelman-Sundberg
2005). CYP2D6 exhibits considerable genetic variation, ranging from no expression to
multiple copies of functional CYP2D6. Individuals can be divided into poor, intermediate,
extensive and ultrarapid metabolisers based on their metabolic capacity (Zanger et al. 2004).
1.4.6. CYP2E1
Although CYP2E1 corresponds to about 15% of the total CYP content in the liver (Rowland-
Yeo et al. 2003, Klein et al. 2006), it participates in the metabolism of relatively few drugs.
Its substrates include paracetamol, chlorzoxazone and several halogenated anaesthetics such
as halothane, enflurane and sevoflurane (Tanaka et al. 2000). However, it is of major
toxicological relevance, as it is involved in the formation of many reactive metabolites (e.g.
the hepatotoxic metabolite of paracetamol) and carcinogens (Tanaka et al. 2000). Ethanol is
also a substrate and inducer of this enzyme (Pelkonen et al. 1998).
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1.4.7. CYP3A subfamily
The CYP3A subfamily consists of CYP3A4, CYP3A5, CYP3A7 and CYP3A43, accounting
for about 30% of the total liver CYP content (Rowland-Yeo et al. 2003, Klein et al. 2006).
The CYP3A subfamily has been estimated to be involved in the metabolism of over 50% of
all drugs (Pelkonen et al. 1998, Wrighton et al. 2000, Gonzalez and Tukey 2006).
CYP3A4 is the most important drug-metabolising enzyme in humans. It is also the most
abundant CYP enzyme in both the intestine and the liver (Zhang et al. 1999, Rowland-Yeo et
al. 2003). Its substrates include atorvastatin, simvastatin, midazolam, triazolam and several
calcium channel blockers (Table 3) (Dresser et al. 2000). Inhibitors of CYP3A4 include
erythromycin, itraconazole, ketoconazole, grapefruit juice and human immunodeficiency
virus (HIV) protease inhibitors (Dresser et al. 2000). CYP3A4 is induced by several drugs,
such as carbamazepine, phenytoin, rifampicin and St John’s wort (Hypericum perforatum)
(Backman et al. 1996a, Backman et al. 1996b, Dürr et al. 2000). There is a high degree of
inter-individual variability in CYP3A4 activity. A number of variant CYP3A4 alleles have
been found, but their frequencies are low, and they do not adequately explain the variability
in CYP3A4 activity (Lamba et al. 2002).
CYP3A5 has a similar spectrum of substrates as CYP3A4. However, there appear to be
certain differences in affinity for particular substrates between the two enzymes (Wrighton et
al. 1990). CYP3A5 is genetically polymorphic, and is expressed in only about 20% of adult
livers in Caucasians. CYP3A7 is the predominant CYP isoform in the foetal liver, but it is
also expressed in some adult livers. A fourth member of the CYP3A subfamily has been
identified, CYP3A43, which in addition to the liver is expressed in the prostate and testis,
but its function is currently not known (Daly 2006).
1.5. Other phase I enzymes
In  addition  to  CYP enzymes,  phase  I  metabolism of  xenobiotics  can  be  catalysed  by  other
drug-metabolising enzymes. Their major difference compared to CYP enzymes is that their
catalytic action is more limited with respect to structure of substrates, and they typically
catalyse only a single type of reaction. Among the most important of these non-CYP
enzymes are flavin-containing monooxygenases (FMOs), monoamine oxidases (MAOs),
alcohol and aldehyde dehydrogenases, and xanthine oxidase. FMOs have overlapping
substrate specificity with CYP enzymes, and they can metabolise e.g. chlorpromazine,
nortriptyline and verapamil (Beedham 1997). MAOs can metabolise both exogenous
monoamines and endogenous monoamine neurotransmitters, and MAO-inhibiting drugs can
be used in the treatment of depression and neurodegenerative conditions such as Parkinson’s
disease (Youdim and Bakhle 2006). Alcohol dehydrogenase is the major metaboliser of
ethanol, producing acetaldehyde, which is further metabolised by aldehyde dehydrogenase.
Xanthine oxidase metabolises xanthine-containing drugs, such as caffeine and theophylline,
and purine analogues (Gibson and Skett 2001). In addition, several esterases can play a role
in the biotransformation of different drugs. For example, carboxylesterases play a major role
in the metabolism of several ester-containing drugs and prodrugs (Imai et al. 2006).
Table 3. Examples of substrates, inhibitors and inducers of some drug-metabolising CYP enzymes.
CYP1A2 CYP2B6 CYP2C9 CYP2C19 CYP2D6 CYP3A4
SUBSTRATES
Caffeine1 Bupropion6 Diclofenac7 Citalopram10 Amitriptyline11 Atorvastatin13
Clozapine2 Cyclophosphamide6 Ibuprofen7 Diazepam10 Codeine11 Cyclosporine13
Rofecoxib3 Efavirenz6 Losartan7 Proguanil10 Fluoxetine11 Felodipine13
Theophylline1 Pethidine6 Phenytoin7 Proton pump inhibitors10 Fluvoxamine11 HIV protease inhibitors13
Tizanidine4 Propofol6 S-warfarin7 S-mephenytoin10 Haloperidol11 Midazolam13
Tolbutamide7 Risperidone11 Simvastatin13
Triazolam13
Verapamil13
INHIBITORS
Ciprofloxacin5 Clopidogrel6 Amiodarone7 Fluvoxamine10 Flecainide11 Clarithromycin13
Fluvoxamine1 Thiotepa6 Fluconazole7 Omeprazole10 Fluoxetine11 Erythromycin13
Furafylline1 Ticlopidine6 Sulphaphenazole7 Moclobemide11 Grapefruit juice13
Sulphamethoxazole7 Paroxetine11 HIV protease inhibitors13
Voriconazole8 Quinidine11 Ketoconazole13
Terbinafine12 Itraconazole13
Voriconazole8
INDUCERS
Tobacco smoke1 Rifampicin6 Rifampicin9 Rifampicin9 Not known11 Carbamazepine1
Phenobarbital6 Phenobarbital9 Phenobarbital9 Phenytoin1
Rifampicin1
1Pelkonen et al. 1998, 2Bertilsson et al. 1994, 3Karjalainen et al. 2006, 4Granfors et al. 2004a, 5Fuhr et al. 1992, 6Turpeinen et al. 2006, 7Miners and Birkett
1998, 8Theuretzbacher et al. 2006, 9Gerbal-Chaloin et al. 2001, 10Desta et al. 2002, 11Zanger et al. 2001, 12Abdel-Rahman et al. 1999, 13Dresser et al. 2000.
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1.6. Conjugating enzymes
Conjugating enzymes attach additional molecules to the nucleophilic or electrophilic sites of
their substrates. Conjugation can occur on functional groups already present on the parent
compound or on groups added by e.g. CYP enzymes. Conjugation reactions generally lead to
more water-soluble products which can be readily excreted in bile or urine (Meyer 1996,
Gibson and Skett 2001).
Glucuronidation is the most common form of conjugation for drugs and endogenous
compounds.  UDP-glucuronosyltransferases  are  a  superfamily  of  enzymes  that  catalyse  the
conjugation of glucuronic acid to their substrates. There are three subfamilies of UGTs in
humans: UGT1A, UGT2A and UGT2B. The UGT isoforms are variably expressed in many
tissues, including the liver, intestine and kidney, and they are located in the endoplasmic
reticulum of the cell. The substrate specificity of UGTs is broad and overlapping, and
includes endogenous steroids, thyroid hormone, bilirubin and retinoic acid, in addition to
xenobiotics (Fisher et al. 2001).
Cytosolic sulfotransferases metabolise a large number of xenobiotics and small endogenous
compounds such as steroids, bile acids and neurotransmitters. SULTs insert a sulfonate
group onto their substrates, with a large overlap in specificity with UGTs. Three SULT
families, SULT1, SULT2 and SULT4 have been identified in humans (Gamage et al. 2006).
Methyltransferases are important in the metabolism of many endogenous compounds and
various drugs. Examples of methyltransferases are thiopurine methyltransferase (TPMT)
which metabolises e.g. 6-mercaptopurine, and catechol O-methyltransferase (COMT) which
metabolises catecholamine neurotransmitters as well as catechol drugs such as L-dopa and
methyldopa (Weinshilboum et al. 1999).
Arylamine N-acetyltransferases (NATs) catalyse the conjugation of an acetyl group from
acetyl coenzyme A (CoA) to their substrates. In humans, there are two NAT isoforms, NAT1
and NAT2. Acetylation is important in the metabolism of aromatic and heterocyclic amine
drugs (Westwood et al. 2006).
Glutathione conjugation is an important mechanism in detoxification of electrophilic
xenobiotics and inactivation of endogenous metabolites during oxidative stress. Cytosolic
glutathione transferases insert a glutathione group onto substrates, resulting in water-soluble
metabolites that are either transported out of the cell or metabolised further (Hayes et al.
2005).
1.7. Drug transporters
The importance of transporters in the pharmacokinetics of drugs has been increasingly
recognised in recent years. In addition to the physiochemical properties of a drug, such as the
acid dissociation constant (pKa), size and lipophilicity, transporter-mediated processes play
an important role in drug disposition. There are two types of drug transporters, uptake and
efflux transporters, and they can affect the extent and direction of drug movement across
organs such as the liver, kidney and brain. In addition to facilitating drug disposition,
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transporters have important roles in transporting endogenous substrates such as sugars,
lipids, amino acids, bile acids, steroids and hormones (Ho and Kim 2005, Shitara et al.
2006).
1.7.1 Uptake transporters
Uptake transporters act by transporting drugs into cells. This class of transporters includes
the organic anion transporting polypeptide (OATP), organic anion transporter (OAT),
organic cation transporter (OCT), organic cation/carnitine transporter (OCTN) and peptide
transporter (PEPT) families (Ho and Kim 2005).
The OATPs are expressed in the intestine, liver, kidney and brain. Humans have 11 OATPs,
of which OATP1B1, OATP1B3 and OATP2B1 are expressed in the sinusoidal membrane of
hepatocytes, and participate in the hepatic uptake of drugs and endogenous substrates. These
three transporters have overlapping selectivity with several clinically important substrates,
such as fexofenadine, methotrexate and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors (statins). OATPs can be inhibited by, for example, cyclosporine,
rifampicin, gemfibrozil and macrolides (Niemi 2007). Numerous genetic polymorphisms in
these transporters have been found (König et al. 2006), and for example the genetic
variability in SLCO1B1 (the gene encoding OATP1B1) has been associated with changes in
the pharmacokinetics of several statins (Niemi et al. 2006, Pasanen et al. 2006, Pasanen et al.
2007).
OATs  are  expressed  at  least  in  the  kidney,  brain  and  placenta.  Four  members  of  this
transporter family have been identified, and their substrates include several NSAIDs, para-
aminohippuric acid, cimetidine and tetracycline (You 2004, Ho and Kim 2005). OCTs and
OCTNs transport organic cations such as endogenous amines and several drugs. Their
messenger ribonucleic acid (mRNA) has been found in the kidney, liver, intestine, brain and
placenta (You 2004). Organic anion and organic cation transport systems play a major role
in the renal elimination of many drugs (Dresser et al. 2001).
1.7.2. Efflux transporters
Efflux transporters export drugs from the cell, often against pronounced concentration
gradients. They can limit entry of drugs into the cell or facilitate their removal from the cell.
The  best  known  drug  efflux  transporter  is  the  P-glycoprotein  (P-gp,  MDR1).  Other  efflux
transporters include the multidrug resistance-associated protein (MRP) family and the breast
cancer resistance protein (BCRP) (Ho and Kim 2005, Fischer et al. 2005).
P-gp can affect the absorption of drugs in the intestine, drug distribution across the blood-
brain barrier and placenta, and biliary and renal excretion of drugs. P-gp has a large number
of substrates, including cyclosporine, digoxin, diltiazem, loperamide, paclitaxel, verapamil
and HIV protease inhibitors. Many, but not all, of the substrates of P-gp are also substrates
for CYP3A4. P-gp is inhibited by cyclosporine, erythromycin, itraconazole and quinidine. P-
gp is also inducible, and induction by rifampicin and St John’s Wort has been reported (Kim
2002, Lin and Yamazaki 2003).
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MRPs are located in the intestine, brain, kidney and liver. They are involved in the transport
of bile salts, steroid hormones, and both unconjugated and conjugated drugs. MRP1, which
is located in various tissues, and MRP3, which is mainly expressed in the liver, transport
their substrates into the bloodstream. Their substrates include methotrexate, etoposide and
vincristine. On the other hand, MRP2 is found in the liver, kidney and intestine, and has
important roles in biliary and renal excretion of endogenous and xenobiotic substrates.
MRP2 has been shown to transport vinca alkaloids, HIV-protease inhibitors, pravastatin,
methotrexate and cisplatin. BCRP is expressed in the intestine, liver and placenta, and its
substrates include doxorubicin, topotecan and zidovudine (Chan et al. 2004, Fischer et al.
2005, Ho and Kim 2005).
1.8. Interaction mechanisms involving drug-metabolising enzymes and
transporters
Inhibition of a drug-metabolising enzyme can result in decreased clearance and increased
plasma concentrations of its substrate drug, and concurrent elevated pharmacological effects
or increased toxicity. On the other hand, induction increases the metabolic capacity of the
affected enzyme. Thus, induction leads to decreased plasma concentrations of the substrate
drug, and often reduced pharmacological activity (Lin and Lu 1998). Inhibition of drug
transporters in the liver, intestine or kidney can cause similar changes, but the effect of
inhibition varies, largely depending on the type (uptake or efflux) and the localisation of the
transporter inhibited. In addition, transporter inhibition can affect the tissue distribution of
drugs, e.g. it can decrease the concentration in the liver. However, interactions involving
drug transporters are still poorly characterised (Ho and Kim 2005).
1.8.1. Inhibition
The mechanisms of enzyme inhibition can be classified roughly into three categories:
reversible, quasi-irreversible and irreversible inhibition. Reversible inhibition is further
categorised into competitive, uncompetitive and mixed type inhibition. In competitive
inhibition, the binding of the inhibitor to the enzyme prevents the binding of the substrate to
the active site of the enzyme. It is believed that inhibitors of this kind share some structural
similarity with the substrates of the inhibited enzyme. Indeed, some inhibitors are also
substrates of the inhibited enzyme, but this is not always the case. On the other hand,
uncompetitive inhibition is characterised by the binding of the inhibitor to the enzyme-
substrate complex, which results in a non-productive complex. However, in practice, mixed
type (competitive-uncompetitive) inhibition is commonly observed in which an inhibitor can
bind both to the free enzyme and to the enzyme-substrate complex. A special case of mixed
type inhibition is noncompetitive inhibition in which the inhibitor does not bind to the active
site of the enzyme and has no effect on substrate binding, but the enzyme-substrate-inhibitor
complex is unable to function catalytically (Hollenberg 2002, Madan et al. 2002).
Irreversible inhibition is characterised by the formation of tightly bound inhibitory
complexes. The distinction between quasi-irreversible and irreversible inhibition is that
quasi-irreversible inhibitors can be removed from the enzyme under specific experimental
conditions, but for irreversible inhibitors this is not possible. Irreversible inhibition requires
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metabolic activation by the enzyme, and is thus often called mechanism-based or suicide
inhibition. As the inhibition is permanent, new enzyme must be formed to regain the
catalytical function. In general, mechanism-based inhibition is considered rare, but in the
case of CYP enzymes it is relatively common, presumably due to the formation of reactive
intermediates during the oxidative process (Hollenberg 2002, Ghanbari et al. 2006).
Compared to reversible inhibition, which is only concentration-dependent, mechanism-based
inhibition is both concentration and time-dependent, and it can be studied by pre-incubating
the inhibitor prior to incubation with the substrate of the index reaction in the in vitro assay
(Venkatakrishnan and Obach 2007). Examples of mechanism-based CYP inhibitors are
rofecoxib for CYP1A2, clopidogrel and ticlopidine for CYP2B6, and erythromycin for
CYP3A4 (Karjalainen et al. 2006, Richter et al. 2004, Turpeinen et al. 2005, Periti et al.
1992).
Although inhibition of drug transporters is a recognised cause of many drug-drug
interactions, the mechanisms of transporter inhibition are not understood in detail (Ho and
Kim 2005). The inhibition of transporters is a complex process and can involve multiple
mechanisms. For example, different drugs can inhibit P-gp by competing for the drug
binding sites of the transporter, by blocking the ATP hydrolysis process, or by both of these
mechanisms (Lin and Yamazaki 2003). In addition, studying transporter inhibition is more
complicated than studying metabolism, because cell-based systems are required and passive
transport must be taken into account (Ho and Kim 2005).
1.8.2. Induction
The net effect of enzyme induction is an increase in the protein levels. Induction of drug-
metabolising enzymes is mediated for the most part by intracellular receptors. The most
important of these receptors are Ah receptor, pregnane X receptor (PXR) and constitutive
androstane receptor (CAR) (Fuhr 2000).
The cytosolic Ah receptor binds to the inducing agent, and forms a heterodimer with the Ah
receptor nuclear translocator (Arnt). The CYP1A subfamily, including the clinically
important CYP1A2, is induced via this mechanism, but other enzymes, such as certain GSTs
and UGTs, can also be affected (Dickins 2004).
The nuclear receptors PXR and CAR mediate the induction of members of the CYP2 and
CYP3 families. They must first bind to the inducing ligand, and thereafter form a
heterodimer with the retinoid X receptor (RXR), which in turn binds to specific
deoxyribonucleic acid (DNA) sequences resulting in increased expression (Willson and
Kliewer 2002). Induction via PXR is caused for example by rifampicin and hyperforin (the
principal constituent in St John’s wort), whereas phenobarbital, phenytoin and
carbamazepine are activators of CAR (Fuhr 2000). In addition to CYP enzymes, many drug-
conjugating enzymes and drug transporters can also be affected by this type of induction
(Tompkins and Wallace 2007). For example, P-gp is induced by rifampicin via PXR (Geick
et al. 2001).
A distinct type of induction is the ability of ethanol to increase CYP2E1 levels by binding to
the active site of the enzyme itself, which leads to the stabilisation of the enzyme protein.
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However, in this case the induction coincides with inhibition, and the induction is only
evident for a short period of time after the exposure to the inducer has stopped. Ethanol-type
induction of CYP2E1 also occurs with many other organic solvents (e.g. acetone and
benzene) and isoniazid (Fuhr 2000).
2. CYP2C8 substrates studied
2.1. Loperamide
Loperamide  is  a  peripherally  acting  µ  opioid  receptor  agonist  which  is  widely  used  in  the
symptomatic treatment of diarrhoea. It lacks the typical central nervous system effects of
opioids, since it has a low oral bioavailability and low penetration through the blood-brain
barrier (Killinger et al. 1979, Dagenais et al. 2004). Loperamide is thought to undergo
considerable first-pass metabolism as the plasma concentrations of parent loperamide are
very low. It  has an elimination half-life (t½) of about 10 to 20 hours (Killinger et al. 1979,
Doser et al. 1995). The recommended initial dose of loperamide is 4 mg and the maximum
daily dose is 16 mg (Imodium label information).
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Figure 1. Chemical structures of loperamide and its major metabolite.
In vitro, loperamide was recently shown to be metabolised predominantly by CYP2C8 and
CYP3A4. The metabolism of loperamide to its main metabolite, N-desmethylloperamide, in
human liver microsomes (HLM) was inhibited by quercetin and ketoconazole, which are
nonselective inhibitors of CYP2C8 and CYP3A4, respectively. In addition, CYP2C8,
CYP3A4, and to a lesser extent CYP2B6, appeared to contribute to loperamide N-
demethylation according to experiments with recombinant human CYP enzymes (rhCYPs)
and a correlation study in HLM (Kim et al. 2004). In addition, loperamide is a substrate of P-
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gp (Dagenais et al. 2004). Concomitant use of loperamide and quinidine, an inhibitor of P-
gp, has resulted in opioid-like central nervous system effects, while resulting in only
moderately raised plasma concentrations of loperamide (Skarke et al. 2003). However,
ritonavir, a strong inhibitor of both CYP3A4 and P-glycoprotein, increased the area under
the concentration-time curve (AUC) of loperamide 2.7-fold without evidence for enhanced
central  nervous  system  effects  (Tayrouz  et  al.  2001).  Furthermore,  the  combination  of  the
CYP2C8 inhibitor trimethoprim and the CYP2C9 inhibitor sulfamethoxazole has been found
to raise the AUC of loperamide 1.9-fold (Kamali and Huang 1996).
2.2. Zopiclone
Zopiclone is a type A ?-aminobutyric acid (GABA) receptor agonist used as a hypnotic
agent. It is chemically unrelated to benzodiazepines, but has a similar pharmacological
profile (Noble et al. 1998). Zopiclone is eliminated mainly by metabolism in the liver with a
t½ of about 4-6 hours. In humans, its main metabolites are N-desmethylzopiclone and
zopiclone-N-oxide (Fernandez et al. 1995). The most common adverse effect of zopiclone is
a bitter aftertaste (Allain et al. 1991). The recommended hypnotic dose of zopiclone is 7.5
mg, or 3.75 mg in elderly patients, but it can be increased to 15 mg in patients not
responding to the lower dose (Noble et al. 1998).
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Figure 2. Chemical structures of zopiclone and its major metabolites.
Zopiclone has been reported to be metabolised to N-desmethylzopiclone and zopiclone-N-
oxide by CYP3A4 and CYP2C8 in vitro. CYP2C8 has been found to be the predominant
enzyme catalysing the formation of zopiclone metabolites in yeast-expressed rhCYPs in
vitro. However, taking into account the relative content of each CYP isoform in the liver,
REVIEW OF THE LITERATURE
28
CYP2C8, CYP2C9 and CYP3A4 would all seem to participate in the metabolism.
Furthermore, the N-desmethylation of zopiclone correlated with CYP3A4 and CYP2C8
activity, whereas the N-oxidation correlated with CYP3A4 activity in different HLM
samples (Becquemont et al. 1999). In humans, the CYP3A4 inhibitors erythromycin and
itraconazole have been reported to raise the AUC of zopiclone by 1.8- and 1.7-fold,
respectively, whereas the concentrations of zopiclone are drastically reduced by the CYP
inducer rifampicin (Aranko et al. 1994, Jalava et al. 1996, Villikka et al. 1997).
2.3. Ibuprofen
Ibuprofen is a widely used NSAID, which is usually administered as a racemic mixture of R-
??)-ibuprofen and S-(+)-ibuprofen. In vivo, about 60% of R-ibuprofen is unidirectionally
converted to S-ibuprofen, which is primarily responsible for the inhibition of
cyclooxygenases 1 and 2 (COX-1 and COX-2) (Adams et al. 1976, Lee et al. 1985, Evans
1992). Ibuprofen is rapidly absorbed, and extensively (>98%) bound to plasma proteins. It
has a t½ of about 2 hours. Racemic ibuprofen is clinically used up to four times daily, with a
maximum total daily dose of up to 2400-3200 mg (Davies 1998). Gastrointestinal toxicity is
a common concern for all NSAIDs, but ibuprofen is regarded as relatively safe compared to
other drugs of this class, at least when low doses are used (Henry et al. 1996).
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Figure 3. Chemical structures of ibuprofen and its major metabolites.
In vitro, ibuprofen is predominantly metabolised by CYP2C9, but CYP2C8 also contributes
to the metabolism of R-ibuprofen. RhCYP2C8 and rhCYP2C9 have been found to contribute
equally to the R-2-hydroxylation of ibuprofen, whereas the R-3-hydroxylation and S-
hydroxylation of ibuprofen were catalysed by rhCYP2C9. At an ibuprofen concentration of
100 µM, other CYP isoforms did not metabolise ibuprofen (Hamman et al. 1997). In healthy
volunteers, the CYP2C9 inhibitors voriconazole and fluconazole have been found to raise
the concentration of S-ibuprofen markedly, but only slightly increase the concentration of R-
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ibuprofen (Hynninen et al. 2006). The CYP2C9*3 allele has been shown to be associated
with a reduced S-ibuprofen clearance (Kirchheiner et al. 2002). On the other hand, the
CYP2C8*3 allele has been found to be associated with a decreased clearance of both R- and
S-ibuprofen (García-Martín et al. 2004, Martínez et al. 2005).
2.4. Pioglitazone
The thiazolidinedione pioglitazone is a peroxisome proliferator-activated receptor gamma
(PPAR-?)  agonist  used  in  the  treatment  of  type  2  diabetes.  The  oral  bioavailability  of
pioglitazone is over 80%, and it is highly (>97%) bound to plasma proteins. Pioglitazone is
extensively metabolised in the liver. The main metabolites in humans are M-IV and M-III (a
secondary metabolite formed from M-IV), which are also pharmacologically active,
contributing significantly to the therapeutic effect. The terminal t½ of pioglitazone ranges
from  3  to  9  hours,  while  the  t½ of M-IV and M-III are considerably longer (Eckland and
Danhof 2000). Adverse effects of pioglitazone are weight gain, peripheral oedema and fluid
retention, which can lead to or exacerbate heart failure. Pioglitazone is administered once
daily at a dosage of 15 or 30 mg, with titration to 45 mg if necessary (Waugh et al. 2006).
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Figure 4. Chemical structures of pioglitazone and its major metabolites.
In vitro, pioglitazone is metabolised predominantly by CYP2C8 and CYP3A4. The
metabolism of pioglitazone is inhibited by CYP2C8 and CYP3A4 inhibitors in HLM, and
recombinant  CYP2C8 and  CYP3A4 are  the  main  isoforms that  catalyse  the  metabolism of
pioglitazone in vitro (Hanefeld 2001, Jaakkola et al. 2006c). In vivo, the CYP3A4 inhibitor
itraconazole has been shown to have virtually no effect on the pharmacokinetics of
pioglitazone,  while  the  AUC  of  pioglitazone  has  been  found  to  be  raised  3.2-fold  by  the
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CYP2C8 inhibitor gemfibrozil (Jaakkola et al. 2005). The CYP inducer rifampicin
substantially decreases plasma concentrations of pioglitazone (Jaakkola et al. 2006a).
Pioglitazone has been reported to inhibit CYP2C8 and CYP3A4 in vitro (Sahi et al. 2003,
Walsky et al. 2005a), but it does not increase plasma concentrations of the CYP2C8 and
CYP3A4 substrate repaglinide in healthy volunteers (Kajosaari et al. 2006a).
Pioglitazone is a competitive inhibitor of OATP1B1 in vitro, and thus could be a substrate
(Nozawa et al. 2004). However, the pharmacokinetics of pioglitazone are not affected by the
SLCO1B1 c.521T>C polymorphism, suggesting that OATP1B1 does not play a significant
role in the pharmacokinetics of pioglitazone (Kalliokoski et al. 2007). The effects of other
genetic polymorphisms on pioglitazone metabolism had not been characterised prior to this
thesis work.
2.5. Repaglinide
Repaglinide is a short-acting meglitinide-analogue antidiabetic drug. It is used to reduce
postprandial glucose levels in patients with type 2 diabetes. Repaglinide has a considerable
first-pass metabolism and an oral bioavailability of about 60%. Repaglinide is extensively
(>98%) protein bound, and it is eliminated rapidly with a t½ of about 1 hour (Hatorp et  al.
1999, Hatorp 2002). Repaglinide is administered before meals in a dose range of 0.5-4 mg,
and the recommended maximum daily dose is 16 mg (NovoNorm product information). The
most common adverse effect of repaglinide is hypoglycaemia (Culy and Jarvis 2001).
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Figure 5. Chemical structures of repaglinide and its major metabolites.
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Repaglinide is extensively metabolised in the liver, and less than 2% of the dose is excreted
unchanged. In humans, the main metabolites of repaglinide are M1, M2 and M4 (van
Heiningen et al. 1999). In vitro, repaglinide is metabolised predominantly by CYP2C8 and
CYP3A4 (Bidstrup et al. 2003, Kajosaari et al. 2005a). The inhibition of CYP3A4 in vitro by
cyclosporine and in vivo by telithromycin decreases the formation of M1 more than M2 and
M4,  indicating  that  CYP3A4  is  important  in  the  formation  of  M1  (Kajosaari  et  al.  2005b,
Kajosaari  et  al.  2006b).  On  the  other  hand,  metabolism  of  repaglinide  to  M4  seems  to  be
primarily catalysed by CYP2C8 (Bidstrup et al. 2003). In pharmacogenetic studies, the
CYP2C8*3 allele has been found to be associated with decreased plasma concentrations of
repaglinide compared to the reference genotype (CYP2C8*1/*1) (Niemi et al. 2003c, Niemi
et al. 2005b). In addition, repaglinide pharmacokinetics are affected by the SLCO1B1
c.521T>C polymorphism, strongly suggesting that repaglinide is a substrate of OATP1B1
(Niemi et al. 2005b). This could also explain why no effect of the CYP2C8 genotype on
repaglinide pharmacokinetics was seen in another study where the SLCO1B1 genotype of the
subjects was not determined (Bidstrup et al. 2006).
The CYP3A4 inhibitors clarithromycin, grapefruit juice, itraconazole, ketoconazole and
telithromycin have been found to moderately raise the plasma concentrations of repaglinide,
with less than 2-fold changes in its AUC (Niemi et al. 2001a, Bidstrup et al. 2006, Niemi et
al. 2003b, Hatorp et al. 2003, Kajosaari et al. 2006b). On the other hand, the CYP2C8
inhibitors gemfibrozil and trimethoprim have been reported to increase the AUC of
repaglinide 8.1-fold and 1.6-fold, respectively (Niemi et al. 2003b, Niemi et al. 2004b).
Additionally, the CYP3A4 and OATP1B1 inhibitor cyclosporine has been found to increase
the AUC of repaglinide 2.4-fold (Kajosaari et al. 2005b). Concentrations of repaglinide are
decreased by rifampicin, but the extent of this interaction is related to the dosing interval
between rifampicin and repaglinide, as rifampicin can both induce and inhibit CYP2C8 and
CYP3A4, as well as OATP1B1, and the inhibitory effect lasts only few hours after
rifampicin dosing (Bidstrup et al. 2004, Kajosaari et al. 2005a, Lau et al. 2007).
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3. CYP inhibitors used in this study
3.1. Gemfibrozil
Gemfibrozil is a fibric acid derivative (fibrate) used in the treatment of
hypertriglyceridaemia. Gemfibrozil is rapidly and completely absorbed from the
gastrointestinal tract. The elimination of gemfibrozil is fast, with a t½ of about 1.5 to 2 hours,
although a terminal t½ of up to 7.6 hours has been reported. The principal metabolite of
gemfibrozil is a benzoic acid derivative, M3 (Todd and Ward 1988). Both the parent
gemfibrozil and its metabolites form glucuronide conjugates, and the primary enzyme
responsible for gemfibrozil glucuronidation in humans seems to be UGT2B7 (Mano et al.
2007). Gemfibrozil is used clinically at a dose of 600 mg twice daily.
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Figure 6. Chemical structures of gemfibrozil and gemfibrozil 1-O-?-glucuronide.
Gemfibrozil is the most potent known inhibitor of CYP2C8 in vivo.  It  raises  the  plasma
concentrations of several CYP2C8 substrates, such as repaglinide (8.1-fold increase in
AUC), cerivastatin (5.6-fold increase in AUC), pioglitazone (3.2- and 3.4-fold increase in
AUC) and rosiglitazone (2.3-fold increase in AUC) (Niemi et al. 2003b, Backman et al.
2002, Jaakkola et al. 2005, Deng et al. 2005, Niemi et al. 2003a). The strong in vivo
inhibitory potential of gemfibrozil is possibly explained by its 1-O-?-glucuronide, which is a
mechanism-based inhibitor of CYP2C8 (Shitara et al. 2004, Ogilvie et al. 2006). On the
other hand, gemfibrozil markedly raises the plasma concentrations of other statins, such as
simvastatin, lovastatin, atorvastatin, pravastatin and rosuvastatin, that are not significantly
metabolised by CYP2C8 (Neuvonen et al. 2006). Indeed, gemfibrozil and its metabolites
have been reported to also inhibit other drug-metabolising enzymes and transporters (Table
4). This can partially explain some of the drug interactions caused by gemfibrozil, but the
exact contribution of the different interaction mechanisms is not clear. In addition,
gemfibrozil has been reported to induce CYP2C8 and CYP3A4 in human hepatocytes, but
the clinical relevance of this finding has not been clarified (Prueksaritanont et al. 2005).
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Table 4. Comparison of the inhibition potency of gemfibrozil and its metabolites on
different CYPs and drug transporters ranked by in vitro IC50 values.
CYP2C8 CYP2C9 CYP3A4 OATP1B1 OAT3 P-gp
Gemfibrozil + 1-3 ++ 3, 4 - 2,4 +(+) 2, 5, 6 ++ 7 - 6
 with preincubation + 3 ++ 3 - 3
Gemfibrozil 1-O-?-
glucuronide ++ 2, 3 - 3 - 3 ++ 2, 5 ++ 7
 with preincubation +++ 3 - 3 - 3
M3 - 2 - 2 - 2, 5 ++ 7
1Wang et al. 2002b, 2Shitara et al. 2004, 3Ogilvie et al. 2006, 4Wen et al. 2001, 5Nakagomi-Hagihara
et al. 2007b, 6Yamazaki et al. 2005, 7Nakagomi-Hagihara et al. 2007a.
IC50, inhibitor concentration producing 50% decrease in activity
- no inhibition
+ weak inhibition (IC50 about 100 µM)
++ moderate inhibition (IC50 about 10 µM)
+++ strong inhibition (IC50 about 1 µM)
3.2. Itraconazole
Itraconazole is a triazole antifungal agent that inhibits the fungal P450 enzyme lanosterol-
14?-demethylase, thereby interfering with fungal cell membrane ergosterol synthesis.
Itraconazole is extensively bound to plasma proteins and only about 0.2% is unbound in
plasma. Itraconazole accumulates in tissues such as the skin, nails, kidney and liver.
Itraconazole is metabolised to several metabolites in the liver, and the major metabolite in
humans is hydroxyitraconazole, which reaches higher plasma concentrations than the parent
itraconazole, and has considerable antifungal activity as well. Elimination of itraconazole is
biphasic, with a terminal t½ of 20 to 24 hours after a single dose, which increases to 30 hours
at steady state (Grant and Clissold 1989, De Beule and Van Gestel 2001). The recommended
daily dose range of itraconazole is 100-400 mg.
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Figure 7. Chemical structure of itraconazole.
Itraconazole potently inhibits CYP3A4 in vitro (Back and Tjia 1991). In vivo, it greatly
increases the concentrations of drugs that are predominantly metabolised by CYP3A4, such
as midazolam, triazolam and simvastatin (Olkkola et al. 1994, Neuvonen et al. 1998, Varhe
et al. 1994). The in vitro and in vivo inhibitory potential of itraconazole seems to be partly
explained by its metabolites, including hydroxyitraconazole (Isoherranen et al. 2004,
Templeton et al. 2007). Itraconazole also inhibits P-gp, affecting the plasma concentrations
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and renal excretion of its substrates, e.g. digoxin (Jalava et al. 1997, Wang et al. 2002a). On
the other hand, the plasma concentrations of itraconazole can be affected by concomitant use
of drugs that inhibit or induce CYP3A4 (Albengres et al. 1998). In addition, gemfibrozil has
been found to decrease the plasma concentrations of itraconazole (Niemi et al. 2003b,
Jaakkola et al. 2005).
3.3. Trimethoprim
Trimethoprim is a dihydrofolate reductase inhibitor, which inhibits the synthesis of bacterial
DNA. Trimethoprim alone and in combination with sulphonamides has been widely used to
treat urinary and respiratory tract infections (Smilack 1999, Masters et al. 2003).
Trimethoprim is well absorbed from the gastrointestinal tract, and is excreted mostly
unchanged in the urine, with a t½ of 8-14 hours. About 10-20% of trimethoprim is
metabolised, but the enzymes involved in its biotransformation are not known (Masters et al.
2003). Trimethoprim is typically used at a dose of 160 mg twice daily.
N
N
O
O
O
NH2
NH2
CH3
CH3
CH3
Trimethoprim
Figure 8. Chemical structure of trimethoprim.
Trimethoprim is a selective and moderately potent inhibitor of CYP2C8 in vitro,  with  an
inhibition constant (Ki) of 32 µM and little effect on other CYP isoforms at concentrations
<100 µM (Wen et al. 2002). In humans, it has been reported to raise the concentrations of
the CYP2C8 substrates rosiglitazone and repaglinide by 1.4- and 1.6-fold, respectively
(Niemi et al. 2004a, Niemi et al. 2004b). In addition, rifampicin has been reported to reduce
the plasma concentrations of trimethoprim (Ribera et al. 2001).
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AIMS OF THE STUDY
The aim of this thesis work was to investigate the effects of CYP2C8-inhibiting drugs on the
pharmacokinetics of drugs metabolised by CYP2C8 in order to clarify its role in drug
metabolism. Furthermore, the pharmacogenetics of CYP2C8 and the inhibition mechanism
of gemfibrozil on CYP2C8 were studied.
Specific aims of the studies were:
I To investigate the effects of the CYP2C8 inhibitor gemfibrozil, the CYP3A
inhibitor itraconazole and their combination on the pharmacokinetics and
pharmacodynamics of loperamide, to determine the role of these enzymes in the
metabolism of loperamide in vivo.
II To investigate the effect of gemfibrozil on the pharmacokinetics and
pharmacodynamics of zopiclone in vivo,  and  the  effect  of  different  CYP
inhibitors on the metabolism of zopiclone in vitro, to determine the importance of
CYP2C8 in the metabolism of zopiclone.
III To investigate the effect of gemfibrozil on the pharmacokinetics of racemic
ibuprofen in vivo, in order to determine the role of CYP2C8 in the metabolism of
ibuprofen enantiomers in vivo.
IV To investigate the effects of the CYP2C8 inhibitor trimethoprim and the
CYP2C8*3 allele on the pharmacokinetics of pioglitazone in vivo, and the effect
of trimethoprim on the metabolism of pioglitazone in vitro.
V To  investigate  the  effect  of  dosing  interval  on  the  extent  of  gemfibrozil-
repaglinide interaction, in order to clarify the mechanism of the interaction and to
determine if the interaction could be avoided by increasing the interval between
administration of gemfibrozil and repaglinide.
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1. Subjects
A total of 56 (36 male, 20 female) healthy volunteers participated in the studies (Table 5).
Two of the male subjects participated in two of the studies. The volunteers were ascertained
to be healthy by medical history, physical examination, and routine laboratory tests before
entering the study. None of the subjects was using continuous medication, oral
contraceptives  or  was  a  frequent  smoker.  The  use  of  any  other  drugs  was  prohibited  one
week prior to each study. Participation in any other trial and blood donation within 4 weeks
before and after the study were also prohibited.
Table 5. Characteristics of the subjects.
Study Subjects
(male/female)
Age (y) Weight (kg) BMI (kg/m2)
I 12 (6/6) 21 ± 2 70 ± 14 22 ± 3
II 10 (7/3) 23 ± 2 74 ± 10 23 ± 2
III 10 (8/2) 21 ± 2 77 ± 5 24 ± 2
IV 16 (8/8) 21 ± 1 68 ± 12 22 ± 3
V 10 (9/1) 23 ± 3 79 ± 12 24 ± 1
Age, weight and body mass index (BMI) data are mean ± SD (standard deviation).
2. Study designs
The  studies  were  carried  out  in  the  Department  of  Clinical  Pharmacology,  University  of
Helsinki. Studies I to IV had a randomised, placebo-controlled, crossover design (Table 6).
Study V had a randomised, open, crossover design. The studies consisted of 2 to 5 phases. In
each phase, a pre-treatment period with the inhibitor drug under study or placebo (no pre-
treatment in study V) was followed by the study day, during which a single oral dose of the
study drug was ingested.
The pre-treatment medications, placebos and the study drugs were supplied, packed and
labelled according to a randomisation list for each subject by the Helsinki University Central
Hospital Pharmacy. Repaglinide tablets were halved and weighed by the investigators. Drug
doses were chosen to reflect current clinical use. A low dose of repaglinide was chosen for
safety reasons.
The study drugs were administered orally with 150 ml water after an overnight fast at 09:00
on the study day. In studies I to IV, the subjects received a standard warm meal 3 hours, and
light meals 7 and 11 hours (7 and 9 hours in study I) after the study drug intake. In study V,
the subjects received a standardised breakfast (eaten in 10 minutes) precisely 15 minutes
after repaglinide administration, 2 standardised snacks (eaten in 5 minutes) after 1 and 2
hours, a standard warm meal after 3 hours, and snacks after 7 and 9 hours. Food intake was
identical in the different study phases.
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Table 6. Structure of the studies.
Study Pre-treatment medication
and dose
Duration of pre-
treatment
(number of doses)
Washout
period
(weeks)
Study drug and
dose
I Gemfibrozil 600 mg x 2
Itraconazole 100 mg x 2
  (first dose 200 mg)
Gemfibrozil and itraconazole
Placebo x 2
10 doses 4 Loperamide 4 mg
on day 3 at 09:00
II Gemfibrozil 600 mg x 2
Placebo x 2
6 doses 2 Zopiclone 7.5 mg
on day 3 at 09:00
III Gemfibrozil 600 mg x 2
Placebo x 2
6 doses 2 Ibuprofen 400 mg
on day 3 at 09:00
IV Trimethoprim 160 mg x 2
Placebo x 2
12 doses 4 Pioglitazone 15 mg
on day 3 at 09:00
V Gemfibrozil 600 mg x 2
No pre-treatment
5 doses 3 Repaglinide 0.25 mg
at 09:00 either 0, 3, 6
or 12 h after last
gemfibrozil dose
During the study days the subjects were under direct medical supervision. During the days of
loperamide and zopiclone administration, naloxone and flumazenil, the antidotes for the
drugs, respectively, were available for use. During the days of repaglinide administration,
blood glucose levels were monitored throughout the day. Additional carbohydrates were
given for symptomatic hypoglycaemia, or if blood glucose concentration dropped below 2.0
mmol/l. In addition, glucose solution for intravenous use and glucagon for intramuscular use
were available.
3. Blood and urine sampling
On the days of study drug administration, a forearm vein of each subject was cannulated for
blood sampling. Timed blood samples (5 or 10 ml each) were collected into tubes containing
ethylenediaminetetraacetic acid (EDTA). In study V, blood glucose concentrations were
measured immediately after each blood sampling by the glucose oxidase method (Precision
G Blood Glucose Testing System; Medisense, Bedford, Mass., USA). Plasma was separated
within 30 min of sampling, and samples were stored at ?70 °C until analysis.
Urine was collected cumulatively in fractions of ?1-12, 12-24, 24-36 and 36-48 hours in
study I, and in fractions of 0-12 and 12-24 hours in study II. After each collection period, the
volume of urine was measured and an aliquot was stored at ?70 °C until analysis.
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4. In vitro studies
The in vitro metabolism of zopiclone and pioglitazone was studied in studies II and IV,
respectively. Pooled HLM, rhCYP2C8 and rhCYP3A4 were purchased from BD Biosciences
(BD Gentest; Woburn, Mass., USA). According to the producer, human liver tissue had been
collected in accordance with all pertinent regulations, and the procedures for organ
collection had been reviewed and accepted by the respective institutional Human Subjects
Committees. The study drugs and other chemicals were purchased from commercial sources.
Incubations were carried out in 0.1 M sodium phosphate buffer (pH 7.4), containing 5.0 mM
MgCl2 and 1.0 mM ?-NADPH. The incubations contained 2.0 mg/ml microsomal protein
with  zopiclone,  and  0.3  mg/ml  microsomal  protein  or  20  pmol/ml  recombinant  CYP  with
pioglitazone. The other components were premixed, and the incubations were initiated by
addition of the ?-NADPH. The study drugs were dissolved in methanol and the final
methanol concentration was 1% in all incubations. The samples were incubated in duplicate
at 37 °C in a shaking water bath. The incubation time was 60 min for zopiclone and 8 min
for pioglitazone. The mean values of the duplicates were used in the calculations.
To investigate the effects of different CYP inhibitors on the metabolism of zopiclone in
HLM, ketoconazole (0.1 µM and 1 µM) and itraconazole (0.8 µM and 8 µM) were used as
inhibitors of CYP3A4, montelukast (1.6 µM and 16 µM) as an inhibitor of CYP2C8,
gemfibrozil  (20  µM  and  200  µM)  as  an  inhibitor  of  CYP2C8  and  CYP2C9,  and
sulphaphenazole (1 µM and 10 µM) as an inhibitor of CYP2C9. The final concentrations of
all inhibitors were chosen based on previously published reports (Baldwin et al. 1995, Wen
et al. 2001, Wang et al. 2002b, Isoherranen et al. 2004, Walsky et al. 2005b).
The Michaelis-Menten constant of pioglitazone (Km) and the maximum reaction velocity
(Vmax) of pioglitazone M-IV metabolite formation were determined by incubating
pioglitazone (0.375-50 µM) with HLM, rhCYP2C8, and rhCYP3A4. The Ki for
trimethoprim was determined by coincubating pioglitazone (1.25-10 µM) and trimethoprim
(0-200 µM) with either HLM or rhCYP2C8. The Km, Vmax and Ki values were calculated by
fitting different kinetic models to the data using nonlinear regression analysis with the
program SigmaPlot for Windows, version 9.01 (Systat Software Inc., San Jose, Calif., USA)
5. Determination of plasma and urine drug concentrations
The concentrations of the study drugs, pre-treatment drugs, and their metabolites were
determined using PE SCIEX liquid chromatography-tandem mass spectrometry (LC-MS-
MS)  systems  (Sciex  Division  of  MDS,  Toronto,  Ontario,  Canada)  or  high-performance
liquid  chromatography  (HPLC)  with  ultraviolet  detection  (Table  7).  When  no  authentic
reference compound was available, the concentrations of the metabolites were measured as
arbitrary units (u/ml) based on the ratio of the peak height of each metabolite to that of the
internal standard in the chromatogram.
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Table 7. The quantification of analytes in pharmacokinetic studies I to V.
Study Analytes quantified Method
used
Limit of
quantification
Interday
CV b
I Loperamide and N-desmethylloperamide a LC-MS-MS 0.05 ng/ml <11%
Gemfibrozil HPLC-UV 0.1 µg/ml <7%
Itraconazole and hydroxyitraconazole HPLC-UV 10 ng/ml <6%
II Zopiclone and N-desmethylzopiclone a LC-MS-MS 0.025 ng/ml <5%
 Zopiclone-N-oxide LC-MS-MS 0.1 ng/ml <5%
Gemfibrozil HPLC-UV 0.1 µg/ml <7%
III R-(?)- and S-(+)-ibuprofen HPLC-UV 0.1 µg/ml <4%
Gemfibrozil HPLC-UV 0.1 µg/ml <7%
IV Pioglitazone LC-MS-MS 0.1 ng/ml <11%
 M-III LC-MS-MS 0.1 ng/ml <8%
 M-IV LC-MS-MS 0.1 ng/ml <14%
Trimethoprim HPLC-UV 0.1 µg/ml <5%
V Repaglinide, M1, M2 and M4 a LC-MS-MS 0.02 ng/ml <6%
Gemfibrozil LC-MS-MS 0.02 ng/ml <9%
 Gemfibrozil 1-O-?-glucuronide LC-MS-MS 0.1 µg/ml <15%
a Limit of quantification and CV is for the parent drug, no reference compound for the metabolite
b Interday coefficient of variation (CV) of the assay at relevant concentrations.
6. Pharmacokinetic calculations
The pharmacokinetics of the study drugs, and their metabolites if applicable, were
characterised by peak concentration (Cmax), time to peak concentration (tmax), t½, AUC from
time 0 to infinity (AUC0-?) and to the last point of measurement (AUC0-t). The Cmax and tmax
values  were  taken  directly  from  the  original  data.  The  terminal  log-linear  part  of  each
concentration-time curve was identified visually for each subject. The elimination rate
constant (ke) was determined by linear regression analysis of the log-linear part of the
plasma concentration-time curve. The t½ was calculated by the equation t½ =  ln2/ke. The
AUC values were calculated by use of the linear trapezoidal rule for the rising phase of the
plasma concentration-time curve and the log-linear trapezoidal rule for the descending phase,
with extrapolation to infinity, when appropriate, by dividing the last measured concentration
by ke. In studies I and II, the amounts of loperamide and zopiclone excreted into urine (Ae)
within 48 hours and 24 hours, respectively, were calculated. The renal clearances (Clrenal) of
loperamide and zopiclone were calculated as Clrenal = Ae/AUC for the corresponding time
interval. In study IV, apparent formation rate constants (kf) were calculated for pioglitazone
metabolites M-IV and M-III by individual modelling with a 1-compartment first-order
formation model. The pharmacokinetic calculations were performed with the program MK-
model, version 5.0 (Biosoft, Cambridge, UK).
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7. Pharmacodynamic measurements
7.1. Psychomotor performance (Studies I and II)
In  studies  I  and  II,  psychomotor  performance  of  each  subject  was  assessed  before  the
administration of the study drug and immediately after each blood sampling, up to 12 hours.
The  Digit  Symbol  Substitution  Test  (DSST)  has  been  demonstrated  to  be  sensitive  for
measuring both cognitive and motor effects of psychoactive drugs (Stone 1984). In this test,
the volunteer substitutes digits (1-9) for simple coded symbols. The number of correctly
substituted digits in 2 minutes was recorded. Before the study started, the volunteers were
properly trained to perform the test.
Subjective drowsiness and drug effect were evaluated on a 100-mm-long horizontal visual
analogue scale (VAS) with adjectives with opposite meanings at both ends. The scale ranged
from Alert to Drowsy, and No drug effect to Maximal drug effect, respectively, expressed in
Finnish.  The  subject  puts  a  mark  on  this  scale  as  a  self-rating  of  his  or  her  feelings  at  the
moment.
For each pharmacodynamic variable, the area under the effect-time curve from 0 to 12 hours
(AUEC0-12 h) was calculated by the linear trapezoidal rule. In addition, the maximum
response for each pharmacodynamic variable was recorded.
7.2. Blood glucose (Study V)
In study V, the pharmacodynamic effects of repaglinide were characterised by baseline
blood glucose concentration, minimum blood glucose concentration and mean blood glucose
concentration from 0 to 9 hours. The mean concentrations were calculated by dividing the
area under the blood glucose concentration-time curve by the corresponding time interval.
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8. Genotyping
For genotyping in studies III, IV and V, an EDTA blood sample was drawn from each
subject and stored at ?20 °C prior to genomic DNA extraction using standard methods
(Qiaamp DNA Blood Mini Kit; Qiagen, Hilden, Germany). The genotyping was performed
using validated Taqman allelic discrimination assays in an Applied Biosystems 7300 Real-
Time polymerase chain reaction (PCR) system (Foster City, Calif., USA).
In studies III and V, the subjects were retrospectively genotyped for selected
polymorphisms. In study III, the CYP2C8 and CYP2C9 genotypes were determined by
investigating the presence of CYP2C8*3 (c.416G>A and c.1196A>G), CYP2C8*4
(c.792C>G), and CYP2C9*2 (c.430C>T) and CYP2C9*3 (c.1075A>C) alleles. In study V,
the presence of CYP2C8*3 and CYP2C8*4 alleles,  as  well  as  the  c.521T>C  SNP  in  the
SLCO1B1 gene, was investigated.
In study IV, the subjects were recruited from a pool of more than 400 pharmacogenetically
characterised subjects genotyped for CYP2C8 alleles. The participants were prospectively
selected on the basis of their CYP2C8 genotype and allocated into three groups:
CYP2C8*1/*1 (i.e., non-carriers of CYP2C8*3; n=8), CYP2C8*1/*3 (n=5), and
CYP2C8*3/*3 (n=3). Only non-carriers of the CYP2C8*4 allele were recruited.
9. In vitro-in vivo correlations
In study IV, the relationship between the in vitro inhibition of pioglitazone metabolism and
the increase in the AUC of pioglitazone by trimethoprim (AUCinhibited /  AUCcontrol) was
investigated by fitting the following equation to the observed individual data using linear
regression analysis:
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where Cliver / Cplasma ratio = concentration of trimethoprim in liver (unbound, available
to enzyme) / concentration (total) of trimethoprim in plasma
Ki = the observed Ki of trimethoprim
Cavg,trimethoprim = the observed average (total) plasma concentration of
trimethoprim, which was calculated as follows:
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where AUC0-13h = the AUC of trimethoprim during the study day
The regression analysis was performed with SPSS for Windows, version 15.0.1. (SPSS Inc,
Chicago, Ill., USA).
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10. Statistical analysis
The results are expressed as mean (range) values, unless otherwise specified. In studies II
and III, the pharmacokinetic and pharmacodynamic variables between the phases were
compared with the paired t-test, or in the case of tmax, with the Wilcoxon signed-rank test. In
studies I and V, the variables were compared with repeated measures analysis of variance
(ANOVA), followed by a posteriori testing with the paired t-test. Bonferroni correction was
applied to multiple comparisons in study I, but uncorrected P values were used in study V to
avoid false negative conclusions and because the direction of the interaction had been
documented previously. The tmax values were compared with Friedman’s ANOVA followed
by  the  Wilcoxon  signed-rank  test.  In  study  IV,  the  pharmacokinetic  variables  between  the
placebo and trimethoprim phases were compared with repeated measures ANOVA with the
CYP2C8 genotype as a between-subjects factor. The differences between genotype groups
were tested with 1-way ANOVA and post hoc comparisons with least significant differences.
When an interaction was observed, the Pearson correlation coefficient was used to
investigate the possible relationships between pharmacokinetic variables of the pre-treatment
drug and the extent of interaction. The differences were considered statistically significant
when P was < 0.05. The statistical analysis was performed with SPSS for Windows (SPSS
Inc, Chicago, Ill., USA).
11. Ethical considerations
The study protocols were approved by the Ethics Committee for Studies in Healthy Subjects
and Primary Care (studies I and II) or by the Coordinating Ethics Committee (studies III, IV
and  V)  of  the  Helsinki  and  Uusimaa  Hospital  District,  as  well  as  the  Finnish  National
Agency for  Medicines.  Before  entering  the  studies,  all  subjects  had  received  both  oral  and
written information, and had given their written informed consent.
RESULTS
43
RESULTS
1. Effects of gemfibrozil on CYP2C8 substrates (Studies I, II and III)
1.1. Loperamide (Study I)
Gemfibrozil raised the AUC0-? and Cmax of loperamide 2.2-fold (P < 0.05) and 1.6-fold (P <
0.05), respectively, and prolonged the t½ of loperamide from 11.9 to 16.7 hours (P < 0.01;
Figures 9 and 10). Itraconazole raised the AUC0-? and  Cmax of loperamide 3.8-fold (P <
0.001) and 2.9-fold (P < 0.001), respectively, and prolonged the t½ of loperamide to 18.7
hours (P < 0.001). The combination of itraconazole and gemfibrozil raised the AUC0-? and
Cmax of loperamide 12.6-fold (P < 0.001) and 4.2-fold (P < 0.001), respectively, and
prolonged the t½ of loperamide to 36.9 hours (P < 0.001).
Figure 9. Effect of gemfibrozil (G),
Itraconazole (I) and their combination
(G+I) on the AUC0-? of loperamide in
study I. The mean AUC0-? values for
loperamide during the inhibitor phases are
given as percentages of the mean values
from the control (placebo) phase. The
error bars depict the ranges of individual
percentages of control values.
* P < 0.05 versus control.
Gemfibrozil  and  the  combination  of  gemfibrozil  and  itraconazole  reduced  the  Clrenal of
loperamide by 28% (P < 0.05) and 34% (P < 0.01), respectively. Gemfibrozil, itraconazole
and their combination reduced the plasma AUC0-72 h ratio of N-desmethylloperamide to
loperamide by 46%, 65% and 88%, respectively (P < 0.001).
No significant differences between the phases were seen in the effects of loperamide on
performance in DSST, or in subjective drowsiness.
The plasma concentrations of itraconazole and hydroxyitraconazole were markedly lower
during the gemfibrozil-itraconazole phase than during the itraconazole phase. Gemfibrozil
reduced the mean Cmax and AUC0-13 h of itraconazole by 57% and 54%, respectively (P <
0.001), and those of hydroxyitraconazole by 37% and 41%, respectively (P < 0.001).
Itraconazole had no significant effect on the plasma concentrations of gemfibrozil on the
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study day. There were no significant correlations between the pharmacokinetic variables of
gemfibrozil, itraconazole and hydroxyitraconazole, and the extent of their interaction with
loperamide.
1.2. Zopiclone (Study II)
Gemfibrozil had no significant effect on any of the pharmacokinetic variables of the parent
zopiclone (Figure 10). The AUC0-? and Cmax of zopiclone during the gemfibrozil phase were
99% and 94% of  control,  respectively.  The  t½ values of zopiclone were 4.7 and 4.8 hours
during the control and gemfibrozil phases, respectively.
Gemfibrozil raised the AUC0-? of the zopiclone metabolites, zopiclone-N-oxide and N-
desmethylzopiclone, by 97% (P < 0.001) and 19% (P < 0.01), respectively, and increased
their Cmax by 62% (P < 0.001) and 16% (P < 0.001), respectively. The Clrenal of zopiclone-N-
oxide was also decreased 48% by gemfibrozil (P < 0.001).
No  significant  differences  between  the  phases  were  seen  in  the  effects  of  zopiclone  on
performance in DSST, or in subjective drowsiness or overall drug effect.
The  Cmax and AUC0-10 h of gemfibrozil were 28.5 µg/ml (range 12.9-40.3 µg/ml) and 92.1
µg·h/ml (range 61.8-124 µg·h/ml), respectively, in the gemfibrozil phase.
In vitro, CYP3A4 inhibitors markedly, and in a concentration dependent manner, inhibited
the depletion of zopiclone (500 nM) in HLM. On the other hand, neither montelukast
(CYP2C8 inhibitor) nor gemfibrozil (CYP2C8 and CYP2C9 inhibitor) had any significant
effect on zopiclone metabolism.
1.3. Ibuprofen (Study III)
Gemfibrozil raised the AUC0-? of R-ibuprofen by 34% (P < 0.001), and prolonged its t½
from 2.9 to 4.5 hours (P < 0.001; Figure 10). Its Cmax and tmax values were not affected by
gemfibrozil.
Gemfibrozil prolonged the t½ of S-ibuprofen from 2.6 to 3.5 hours (P < 0.001), but had no
statistically significant effect on the other pharmacokinetic variables of S-ibuprofen. The
AUC0-? ratio of R-ibuprofen to S-ibuprofen was increased from 0.79 to 0.99 by gemfibrozil
(P < 0.001).
The  Cmax and AUC0-13 h of gemfibrozil were 26.6 µg/ml (range 19.6-35.9 µg/ml) and 78.6
µg·h/ml (range 65.2-99.9 µg·h/ml), respectively, in the gemfibrozil phase.
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Figure 10. Effect of gemfibrozil on the
pharmacokinetics of loperamide (Lop),
zopiclone (Zop), R-ibuprofen (R-ibu) and
S-ibuprofen (S-ibu) in studies I to III. The
mean AUC0-?, Cmax and t½ values during
the gemfibrozil phase are given as
percentages of the mean values from the
control (placebo) phase. The error bars
depict the ranges of individual percentages
of control values.
* P < 0.05 versus control.
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2. Effects of trimethoprim and the CYP2C8 genotype on
pioglitazone (Study IV)
2.1. Effect of trimethoprim
Trimethoprim raised the AUC0-? of parent pioglitazone by 42% (P < 0.001) and prolonged
its  dominant  t½ from 3.9 to 5.1 hours (P < 0.001; Figure 11). However, the Cmax of
pioglitazone was not statistically significantly changed by trimethoprim.
Figure 11. Effect of trimethoprim on the
pharmacokinetics of pioglitazone in study
IV. The mean AUC0-?, Cmax and t½ of
pioglitazone during the trimethoprim
phase are given as percentages of the
mean values from the control (placebo)
phase. The error bars depict the ranges of
individual percentages of control values.
* P < 0.05 versus control.
The AUC0-? of pioglitazone metabolite M-IV was slightly raised (by 10%; P = 0.048), while
the  Cmax and  t½ were unaffected by trimethoprim. The kf of M-IV decreased from 0.17 to
0.10 h-1 (P <  0.001),  and  the  M-IV  to  pioglitazone  AUC0-? ratio  was  also  lowered  by
trimethoprim.
Trimethoprim Cmax and AUC0-13 h were 3.1 µg/ml (range 1.2-4.7 µg/ml) and 28.6 mg·h/ml
(range 7.8-41.9 mg·h/ml), respectively, in the trimethoprim phase. One of the subjects had
exceptionally low concentrations and a short t½ for trimethoprim, and no increase in the
AUC of pioglitazone was observed in this subject.
The extent of trimethoprim-pioglitazone interaction (pioglitazone AUCinhibited / pioglitazone
AUCcontrol) could be predicted on the basis of the in vitro Ki of trimethoprim and its average
plasma concentration using a competitive inhibition model with a Cliver/Cplasma ratio of 2.35
for trimethoprim. The equation obtained using regression analysis explained 24% of the
variability in the extent of interaction.
In vitro, the M-IV metabolite was formed by both rhCYP2C8 and rhCYP3A4. The
metabolite formation by CYP2C8 was best described by a model for Michaelis-Menten
kinetics with substrate inhibition, whereas the formation by CYP3A4 was best described by
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sigmoidal  (Hill)  kinetics.  At  clinically  relevant  pioglitazone  concentrations  (<2  µM),  the
formation  rate  of  M-IV  by  CYP2C8  was  5  to  10  times  higher  than  that  of  CYP3A4.
Trimethoprim inhibited M-IV formation in HLM and recombinant CYP2C8 in a
concentration dependent manner, and the inhibitory effect was best described by the
competitive inhibition model, with Ki values of 38.2 ± 3.9 (mean ± SE, standard error) and
34.1 ± 4.0 µM, respectively.
2.2. Effect of the CYP2C8*3 allele
During the placebo phase, the subjects heterozygous and homozygous for the CYP2C8*3
allele had lower plasma concentrations of pioglitazone than the subjects with the
CYP2C8*1/*1 genotype. The weight-adjusted AUC0-? of pioglitazone was 34% smaller (P <
0.05) in the CYP2C8*3/*3 group and 26% smaller (P <  0.05)  in  the CYP2C8*1/*3 group
than in the CYP2C8*1/*1 group (Figure 12). This difference was also maintained in the
trimethoprim phase for the CYP2C8*3/*3 group (P < 0.05 versus the CYP2C8*1/*1 group).
The extent of the interaction did not appear to depend on the CYP2C8 genotype.
Figure 12. The  individual  AUC0-? values of pioglitazone adjusted for body weight in each
genotype group during placebo (open symbols) and trimethoprim (closed symbols) treatment
in study IV. The horizontal lines depict the mean of each group.
Pioglitazone metabolite M-IV and M-III AUC0-? ratios  to  the  parent  pioglitazone  were
higher in the variant allele-carrier groups than in the control group. However, there were no
statistically significant differences between the genotype groups in the weight-adjusted
AUC0-? values of M-IV and M-III.
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3. Effect of dosing interval on gemfibrozil-repaglinide interaction
(Study V)
Gemfibrozil raised the AUC0-? of repaglinide 7.0-, 6.5-, 6.2-, and 5.0-fold (P < 0.001) when
repaglinide was taken either simultaneously with, or 3, 6 or 12 hours after the last dose of the
gemfibrozil pre-treatment, respectively (Figure 13). The Cmax in each gemfibrozil phase was
about 2-fold greater than in the control phase. The t½ of repaglinide was prolonged from 1.2
hours to 3.0, 2.7, 2.4, and 2.0 hours (P < 0.001) by gemfibrozil with the 0, 3, 6 and 12 hour
dosing intervals, respectively.
The AUC0-3 h of the repaglinide metabolite M4 was reduced by 79% (P < 0.001), 86% (P <
0.001), 77% (P < 0.001) and 38% (P < 0.05) by gemfibrozil with a 0, 3, 6 or 12 hour interval
between gemfibrozil and repaglinide administration, respectively. In contrast, the AUC0-?
values of M1 and M2 were higher during each of the gemfibrozil phases than in the control
phase.  The  Cmax of M4 was greatly, and that of M2 slightly, decreased by gemfibrozil,
whereas the Cmax of M1 was increased. All metabolite to repaglinide AUC ratios were lower
during all gemfibrozil phases than in the control phase (P < 0.001 for M2 and M4, P < 0.05
for M1).
The mean blood glucose concentration from 0 to 9 hours was lower in each of the
gemfibrozil phases than in the control phase (P < 0.005). The minimum blood glucose
concentration was also lowered by gemfibrozil up to the 6 hour dosing interval between
gemfibrozil and repaglinide, compared to control (P < 0.001).
The  Cmax and  AUC0-9  h of gemfibrozil were 42.4 µg/ml (range 26.3-64.4 µg/ml) and 105
µg·h/ml (range 58.2-143 µg·h/ml), and the corresponding values of gemfibrozil 1-O-?-
glucuronide were 29.9 µg/ml (range 20.1-48.7 µg/ml) and 116 µg·h/ml (range 82.8-205
µg·h/ml), when the last gemfibrozil dose was ingested simultaneously with repaglinide. The
observed Cmax values  (during  the  9  hour  period  after  the  administration  of  repaglinide)  of
gemfibrozil and gemfibrozil 1-O-?-glucuronide declined along with the increasing dosing
interval, and during the 12 hour interval phase, these values were only about 5% and 10% of
the respective (actual) Cmax values during simultaneous administration with repaglinide.
There were no significant correlations between the pharmacokinetic variables of gemfibrozil
and its 1-O-?-glucuronide and the extent of interaction with repaglinide.
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Figure 13. The effect of gemfibrozil on
the pharmacokinetics of repaglinide when
repaglinide was administered either
simultaneously with, or 3 h, 6 h or 12 h
after gemfibrozil in study V. The mean
AUC0-?, Cmax and t½ of repaglinide during
the gemfibrozil phases are given as
percentages of the mean values from the
control (placebo) phase. The error bars
depict the ranges of individual percentages
of control values.
* P < 0.05 versus control.
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DISCUSSION
1. Methodological considerations
1.1. In vitro studies
Human liver microsomes (HLM) and recombinant CYP enzymes are well-validated tools for
the investigation of drug metabolism and possible drug-drug interactions in vitro (Rodrigues
1999).  HLMs  contain  all  the  enzymes  present  in  the  endoplasmic  reticulum  of  the
hepatocytes, with their relative abundances conserved. To avoid inter-individual variability,
pooled HLMs were used since they represent the population average more precisely than
single liver samples. On the other hand, rhCYP enzymes contain only one specific CYP
isoform, and are useful in identifying the role of certain CYP isoforms in the metabolism of
a drug.
The aim in study II was to investigate the effect of inhibition of different CYP enzymes on
the elimination of zopiclone. Therefore, a single (clinically relevant) concentration of
zopiclone was incubated with HLM with different selective CYP enzyme inhibitors. In
addition, the metabolism of pioglitazone and the effect of trimethoprim on it were
characterised. For this, the metabolism of pioglitazone was studied in HLM and rhCYP2C8
and rhCYP3A4. The formation rate of the pioglitazone metabolite M-IV was measured since
it is the major primary metabolite of pioglitazone (Eckland and Danhof 2000).
Most drugs are poorly soluble in water, and thus organic solvents are often needed in in vitro
studies.  They  can,  however,  affect  the  enzymatic  activities  of  different  CYP isoforms to  a
varying degree (Chauret et al. 1998). In this work, methanol was used as a solvent in all
(including control) incubations, and its concentrations were kept sufficiently low (1% v/v) to
avoid  significant  effect  on  CYP  enzyme  activity  (Busby  et  al.  1999).  Other  incubation
conditions, such as ionic strength and the pH of the incubation medium, can also affect the
results of in vitro studies (Venkatakrishnan et al. 2001), and thus, 0.1 M sodium phosphate
buffer (pH 7.4) was used as the incubation medium to provide conditions that are equivalent
to those in the hepatic cytoplasm in vivo.
The use of relevant substrate concentration is critical in in vitro studies, especially when only
a single concentration is used. If a drug is metabolised by multiple CYP enzymes, the
contribution of different CYP isoforms to the metabolism can vary greatly depending on the
concentration used (Venkatakrishnan et al. 2001). The plasma concentrations of zopiclone
typically peak at about 60-90 ng/ml (Fernandez et al. 1995). The in vitro zopiclone
concentration  of  500  nM  (194  ng/ml)  was  chosen  to  be  low  enough  to  reflect  a  clinically
relevant level, and high enough to allow reliable quantification of its enantiomer
concentrations. However, the plasma concentrations of a drug do not necessarily reflect the
actual concentrations at the site of metabolism in the hepatocyte (Venkatakrishnan et al.
2001). A range of pioglitazone (0.375-50 µM) concentrations was chosen to investigate the
kinetic parameters of M-IV formation and the relative contribution of CYP2C8 and CYP3A4
in the metabolism of pioglitazone at different concentrations.
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The in vitro study on zopiclone could have been improved by using variable zopiclone
concentrations,  or  by  utilising  rhCYPs.  However,  our  aim  was  to  study  the  role  of  CYP
enzymes, CYP2C8 in particular, in the metabolism of zopiclone at clinically relevant
concentrations. Thus, only a single concentration was chosen. The study on pioglitazone
would have been more comprehensive if the metabolism of pioglitazone had also been
studied with the CYP2C8.3 enzyme. However, this enzyme was not commercially available.
1.2. In vivo studies
The studies performed in healthy volunteers had a randomised, balanced, cross-over design.
Thus, the subjects served as their own controls, limiting the effects of inter-individual
variability, and reducing the number of subjects needed to find a possible clinically
significant interaction. The wash-out periods (2, 3 or 4 weeks) were chosen to minimise the
risk of possible carry-over effects. The wash-out durations were chosen according to the
pharmacokinetic properties of the drugs studied, and taking into account the time necessary
for the synthesis of new CYP enzyme in the case of irreversible inhibition (Ghanbari et al.
2006).
In studies I to IV the pre-treatment dose was administered 1 hour before the study drug to
ensure adequate absorption of the pre-treatment drug by the time the study drug was
ingested. In order to decrease variability in drug absorption, and in study V to decrease
variability in blood glucose concentrations, the subjects fasted overnight and received
standardised meals during the study days. The pre-treatment drug doses were chosen to
reflect normal therapeutic use, and their concentrations were monitored during the study
days and ascertained to be at therapeutic levels. Additionally, to monitor compliance, the
subjects marked the precise timing of drug intake according to the pre-treatment schedule. In
study V, where the effect of variable dosing intervals was investigated, the intake of the last
pre-treatment dose (either at 21:00, 03:00 or 06:00) was ensured by contacting the subjects
by phone.
In  study  V,  a  small  dose  (0.25  mg)  of  repaglinide  was  chosen  for  safety  reasons,  because
healthy subjects are more sensitive to its hypoglycaemic effect than diabetic patients. In an
earlier study, when repaglinide was administered 1 hour after gemfibrozil, gemfibrozil raised
the  mean AUC of  repaglinide  8-fold  (Niemi  et  al.  2003b).  Thus,  it  was  estimated  that  the
pharmacokinetic and pharmacodynamic effects would be similar or lesser when repaglinide
was  administered  simultaneously  with,  or  3,  6  or  12  hours  after  the  last  gemfibrozil  dose.
During the study day, blood glucose concentrations were measured repeatedly, and
additional carbohydrates were given for symptomatic hypoglycaemia or when blood glucose
decreased below 2.0 mmol/l.
The pharmacodynamic tests in studies I and II were used to examine the clinical relevance of
the possible interactions. The VAS scale for studying subjective effects and the DSST test
for studying psychomotor effects are well-validated and widely used for these purposes
(Aranko et al. 1994, Backman et al. 1996a, Granfors et al. 2004b). Before entering the
studies, the subjects were trained to properly perform the DSST test.
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2. Effect of gemfibrozil on loperamide, zopiclone and ibuprofen
Gemfibrozil markedly increased the plasma concentrations of loperamide and moderately
increased those of R-ibuprofen, whereas no effect was observed on the pharmacokinetics of
zopiclone. Each of these drugs has been reported to be metabolised by CYP2C8 in vitro
(Kim et al. 2004, Hamman et al. 1997, Becquemont et al. 1999). The concentrations of
gemfibrozil were similar in each of the three studies, and in line with previous
pharmacokinetic studies with gemfibrozil (Miller and Spence 1998). Thus, a lack of
compliance in gemfibrozil ingestion or its poor absorption would not explain the different
effects of gemfibrozil on these drugs.
Gemfibrozil increased the AUC of loperamide, and reduced the plasma N-
desmethylloperamide to loperamide AUC0-72 h ratio and the ratio of N-desmethylloperamide
to loperamide in urine. Itraconazole had a similar, albeit somewhat stronger, effect on these
variables. The combination of gemfibrozil and itraconazole acted synergistically to further
raise the plasma concentrations of loperamide. This indicates that both gemfibrozil and
itraconazole inhibited the biotransformation of loperamide to its main metabolite, N-
desmethylloperamide. These results are in agreement with previous data showing that
loperamide is biotransformed to N-desmethylloperamide by CYP3A4 and CYP2C8 in vitro
(Kim et al.  2004).  During the gemfibrozil-itraconazole phase,  the plasma concentrations of
both itraconazole and hydroxyitraconazole were considerably lower than during the
itraconazole phase, in line with two other studies (Niemi et al. 2003b, Jaakkola et al. 2005).
This finding could be explained by a reduction in the oral bioavailability of itraconazole
caused by gemfibrozil, or by displacement of itraconazole and hydroxyitraconazole from
plasma proteins by gemfibrozil, leading to increased clearance or volume of distribution.
Although the plasma concentrations of loperamide rose several fold, no changes were
observed in the pharmacodynamics of loperamide in this study with a low single dose of 4
mg loperamide. However, an increased risk of adverse effects or increased efficacy should
be considered when loperamide is used concomitantly with gemfibrozil, itraconazole or their
combination, especially if a higher dose of loperamide is used or it is used on a regular basis.
The pharmacokinetics of zopiclone were unaffected by gemfibrozil. However, the
concentrations of zopiclone-N-oxide and N-desmethylzopiclone were increased by
gemfibrozil,  and  the  Clrenal of zopiclone-N-oxide was lowered. The effects on zopiclone
metabolites could be explained by inhibition of their further metabolism or inhibition of drug
transporters by gemfibrozil. On the other hand, another explanation for these findings could
be induction of CYP3A4, coinciding with inhibition of CYP2C8 by gemfibrozil
(Prueksaritanont et al. 2005). However, as the further elimination pathways of zopiclone
metabolites are not known in detail, the contributions of different mechanisms to providing
an explanation for these findings are not clear. In a previous in vitro study, both CYP3A4
and CYP2C8 contributed to the metabolism of parent zopiclone (Becquemont et al. 1999).
However, these experiments were performed at a supratherapeutic zopiclone (50 µM)
concentration. In contrast, when 500 nM (194 ng/ml) zopiclone was used in study II,
inhibitors of CYP2C8 had only a negligible effect on zopiclone metabolism. This highlights
the importance of using clinically relevant concentrations when in vitro – in vivo correlations
are made. Although parent zopiclone concentrations were unaffected and no changes were
observed in the psychomotor tests, both zopiclone-N-oxide and N-desmethylzopiclone
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possess some pharmacological activity (Goa and Heel 1986, Carlson et al. 2001), and
therefore their increased concentrations could slightly enhance the effects of zopiclone when
administered concomitantly with gemfibrozil.
Gemfibrozil moderately increased the AUC of R-ibuprofen and prolonged its t½, but had
little effect on S-ibuprofen. In humans, both R- and S-ibuprofen are metabolised via 2- and
3-hydroxylation (Tan et al. 2002). In vitro, both CYP2C8 and CYP2C9 participate in the
formation of R-2-hydroxyibuprofen, whereas the formation of S-2-, S-3- and R-3-
hydroxyibuprofen is mainly catalysed by CYP2C9 (Hamman et al. 1997). In healthy
volunteers, the CYP2C9 inhibitors voriconazole and fluconazole raise the plasma
concentrations of S-ibuprofen, whereas their effects on R-ibuprofen are only minor
(Hynninen et al. 2006). The findings that CYP2C8 and CYP2C9 inhibitors only moderately
affect the pharmacokinetics of R-ibuprofen could be explained by alternative pathways in the
elimination of R-ibuprofen. A possible explanation could be the unidirectional conversion of
R-ibuprofen to S-ibuprofen that occurs in vivo via an enzymatic pathway (Tracy et al. 1993).
The clinical significance of the interaction between gemfibrozil and ibuprofen is likely to be
limited, as the therapeutic effects of ibuprofen are mainly mediated by its S-enantiomer, and
as it has a wide therapeutic range (Davies 1998). However, the coadministration of inhibitors
of both CYP2C8 and CYP2C9 with ibuprofen could have greater effects on the
pharmacokinetics of both ibuprofen enantiomers.
3. Effects of trimethoprim and the CYP2C8 genotype on
pioglitazone
Trimethoprim moderately raised the plasma concentrations of pioglitazone. The increase in
the AUC0-? of pioglitazone by trimethoprim (1.4-fold) is in line with previous trimethoprim
interaction studies with the CYP2C8 substrates repaglinide (1.6-fold increase in AUC0-?)
and rosiglitazone (1.4-fold increase in AUC0-?) (Niemi et al. 2004a, Niemi et al. 2004b).
Pioglitazone has been reported to be metabolised by CYP2C8 and CYP3A4 (Hanefeld 2001,
Jaakkola et al. 2006c), but the CYP3A4 inhibitor itraconazole has no significant effect on the
pharmacokinetics of pioglitazone (Jaakkola et al. 2005). Providing a plausible explanation
for this finding, the pioglitazone M-IV metabolite was formed predominantly by CYP2C8 at
low, clinically relevant concentrations (<2 µM), whereas the importance of CYP3A4
increased at higher pioglitazone concentrations due to sigmoidal kinetics of M-IV formation
by rhCYP3A4.
The CYP2C8*3 allele was found to be associated with moderately decreased plasma
concentrations of pioglitazone. Both the weight-adjusted AUC0-? and the M-IV/pioglitazone
and M-III/pioglitazone AUC0-? ratios showed a gene-dose effect, with the values for the
heterozygous CYP2C8*3 allele carriers in between those of the homozygous carriers and the
non-carrier group. Thus, as found previously with repaglinide and rosiglitazone (Niemi et al.
2003c, Kirchheiner et al. 2006), the CYP2C8*3 allele seems to be associated with an
increased metabolic clearance of pioglitazone in vivo.
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Although the opposing effects of trimethoprim and the CYP2C8*3 allele on pioglitazone
were only moderate, trimethoprim increased the AUC of pioglitazone two-fold in some
subjects, and the concentrations of the active metabolite M-IV were also increased by
trimethoprim. The adverse effects of pioglitazone, which include weight gain and fluid
retention,  appear  to  be  dose  (concentration)  dependent  (Waugh  et  al.  2006).  Thus,  the
efficacy and the occurrence of adverse effects of pioglitazone can be altered by drug
interactions and genetic factors that alter CYP2C8 activity.
4. Effect of dosing interval on gemfibrozil-repaglinide interaction
The interaction between gemfibrozil and repaglinide persisted even with an interval of up to
12 hours between gemfibrozil and repaglinide administration, with a 5- to 7-fold mean
increase in the AUC of repaglinide. Notably, the formation of M4, which is predominantly
formed by CYP2C8 (Bidstrup et al. 2003, Kajosaari et al. 2005b), was almost abolished by
gemfibrozil. By the time repaglinide was administered 12 hours after the last dose of
gemfibrozil, the plasma concentrations of gemfibrozil and its 1-O-?-glucuronide had
declined to very low levels. This supports the proposed mechanism-based inhibition of
CYP2C8 by gemfibrozil 1-O-?-glucuronide as the main mechanism of this interaction
(Ogilvie et al. 2006). Moreover, taking into account mechanism-based inhibition of CYP2C8
in a metabolic prediction model has markedly improved the predictions of the interactions of
gemfibrozil with CYP2C8 substrates, compared to competitive inhibition alone (Hinton et al.
2008).  In  addition,  gemfibrozil  is  concentrated  in  the  liver,  at  least  in  rats  (Sallustio  et  al.
1996, Sabordo et al. 1999), and thus, the concentrations of gemfibrozil and gemfibrozil 1-O-
?-glucuronide in the liver can be much higher than those in plasma. The combination of high
intracellular concentrations and mechanism-based inhibition of CYP2C8 could be sufficient
to explain the high inhibition efficiency of gemfibrozil with CYP2C8 substrates
The results of this study have clinical implications concerning gemfibrozil interactions with
repaglinide and CYP2C8 substrates in general. As the degree of interaction remained quite
stable during the typical 12 hour dosing interval of gemfibrozil, the interaction cannot be
avoided by administering gemfibrozil and repaglinide (or another CYP2C8 substrate) at
different times. However, the interactions of gemfibrozil with repaglinide and possibly other
drugs metabolised by CYP2C8 could be managed by decreasing the dose of the substrate
drug, because similar dose adjustment is needed, regardless of the timing of the drug
administration. On the other hand, although the gemfibrozil-repaglinide interaction persisted
for at least 12 hours after the last gemfibrozil dose, it is not known how long this inhibition
potential is maintained. Thus, care is warranted for at least several days when gemfibrozil is
discontinued and a therapy with a drug that is metabolised by CYP2C8 is initiated.
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5. General discussion
The significance of CYP2C8 in drug metabolism has been recognised only recently.
Previously, research on CYP2C8 was hindered by the lack of selective inhibitors and probe
substrates. However, recent findings have provided the means to study CYP2C8-mediated
drug metabolism both in vitro and in vivo.
In vitro, paclitaxel 6-?-hydroxylation has been used as a selective probe reaction to study
CYP2C8 activity (Rahman et al. 1994). More recently, amodiaquine N-desethylation has
been reported to be a selective high affinity and turnover probe reaction for CYP2C8 (Li et
al. 2002). Initially, quercetin was used as a probe in vitro inhibitor of CYP2C8. However, it
has poor selectivity as it can also inhibit other CYPs, e.g. CYP3A4 (Ha et al. 1995). On the
other hand, trimethoprim and especially montelukast are more selective inhibitors of
CYP2C8, although the inhibitory effect of montelukast is highly related to protein
concentration in the incubation medium (Wen et al. 2002, Walsky et al. 2005b). In addition,
inhibitory monoclonal antibodies for CYP2C8 are commercially available (Venkatakrishnan
et al. 2001). It is also of note that compounds previously thought to be selective inhibitors of
other CYP enzymes can also inhibit CYP2C8. For example, ketoconazole and
diethyldithiocarbamate, inhibitors of CYP3A4 and CYP2E1, respectively, cause significant
inhibition of CYP2C8 as well (Ong et al. 2000).
Repaglinide and rosiglitazone have been recommended for use as in vivo probes  for
CYP2C8-mediated metabolism (Huang et al. 2007). In addition, pioglitazone can be
considered as a possible probe substrate. Repaglinide, unlike pioglitazone and rosiglitazone,
easily causes hypoglycaemia when used in healthy volunteers, and therefore, its use
necessitates careful monitoring of blood glucose and follow-up of the subjects. On the other
hand, repaglinide has been found to be the most sensitive CYP2C8 substrate for the effects
of CYP2C8 inhibitors like gemfibrozil and trimethoprim (Niemi et al. 2003b, Niemi et al.
2004b). However, repaglinide is also a substrate of OATP1B1, and its pharmacokinetics is
affected by the SLCO1B1 genotype (Niemi et al. 2005b). In contrast, the pharmacokinetics
of pioglitazone and rosiglitazone are unaffected by the SLCO1B1 genotype (Kalliokoski et
al. 2007). In vitro, the metabolism of rosiglitazone is catalysed mainly by CYP2C8, with a
minor contribution from CYP2C9 (Baldwin et al. 1999), whereas pioglitazone is metabolised
mainly by CYP2C8, and to a lesser degree by CYP3A4 (Jaakkola et al. 2006c). In vivo,
gemfibrozil and trimethoprim raise the AUC of pioglitazone slightly more than that of
rosiglitazone,  suggesting  that  the  role  of  CYP2C8  is  slightly  greater  in  the  metabolism  of
pioglitazone than in the metabolism of rosiglitazone (Niemi et al. 2003a, Niemi et al. 2004a,
Jaakkola et al. 2005). Thus, pioglitazone could serve as a more selective in vivo probe for
CYP2C8 than rosiglitazone, with a better single dose safety profile than repaglinide.
However, reliable monitoring of the pioglitazone active metabolites M-IV and M-III requires
longer blood sampling schedules.
Trimethoprim and gemfibrozil are well established in vivo inhibitors of CYP2C8 (Niemi et
al. 2003b, Niemi et al. 2004b, Huang et al. 2007). To date, many clinically relevant drug
interactions involving CYP2C8 have been found to be caused by these two drugs (Table 8).
On the other hand, some in vitro inhibitors of CYP2C8, such as montelukast and quercetin,
have no effect in vivo (Kim et al. 2005, Kajosaari et al. 2006b, Jaakkola et al. 2006b). Thus,
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other in vivo inhibitors of CYP2C8 that could cause clinically relevant drug interactions are
currently  not  known.  However,  the  CYP3A4  inhibitor  ketoconazole  is  also  a  relatively
potent inhibitor of CYP2C8 in vitro (Ong et al. 2000). Therefore, the effects of ketoconazole
on the metabolism of some drugs in vitro and in vivo may be partially due to inhibition of
CYP2C8. It can be speculated that this may have led to underestimation of the importance of
CYP2C8 in drug metabolism, because ketoconazole is a widely used model inhibitor of
CYP3A4.
Table 8. Drug interaction studies in humans involving inhibition of CYP2C8-mediated
metabolism.
Substrate Inhibitor Fold increase
in AUC
 Reference
Cerivastatin Gemfibrozil 5.59 Backman et al. 2002
Loperamide Gemfibrozil 2.18 Study I
Trimethoprim +
Sulfamethoxazole 1.89 Kamali and Huang 1996
Pioglitazone Gemfibrozil 3.22 Jaakkola et al. 2005
3.39 Deng et al. 2005
Montelukast 0.98 Jaakkola et al. 2006b
Trimethoprim 1.42 Study IV
Zafirlukast 1.00 Jaakkola et al. 2006b
Repaglinide Gemfibrozil 8.12 Niemi et al. 2003b
Gemfibrozil 7.02 Study V
Montelukast 0.99 Kajosaari et al. 2006b
Pioglitazone 0.90 Kajosaari et al. 2006a
Trimethoprim 1.61 Niemi et al. 2004b
R-ibuprofen Gemfibrozil 1.34 Study III
Rosiglitazone Gemfibrozil 2.29 Niemi et al. 2003a
Montelukast 1.02 Kim et al. 2007
Trimethoprim 1.37 Niemi et al. 2004a
1.31 Hruska et al. 2005
Quercetin 0.99 Kim et al. 2005
Zopiclone Gemfibrozil 0.99 Study II
The most notable drug interactions concerning CYP2C8 have been the gemfibrozil-
repaglinide and gemfibrozil-cerivastatin interactions (Niemi et al. 2003b, Backman et al.
2002). Gemfibrozil greatly increased the plasma concentrations of repaglinide and
cerivastatin (8.1- and 5.1-fold increases in AUC, respectively), and considerably enhanced
and prolonged the blood glucose lowering effect of repaglinide. Cerivastatin, which is
predominantly metabolised by CYP2C8 (Wang et al. 2002b), was withdrawn from the
market in 2001 after an increase in the occurrence of rhabdomyolysis, including several fatal
cases. In many of these incidents, cerivastatin had been used concomitantly with gemfibrozil
(Staffa et al. 2002). Although other mechanisms could have contributed to this interaction,
the increase in cerivastatin concentrations by gemfibrozil likely played a major role in the
occurrence of these serious adverse effects (Backman et al. 2002, Neuvonen et al. 2006).
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In vitro, parent gemfibrozil is a more potent inhibitor of CYP2C9 than of CYP2C8 (Wen et
al. 2001, Wang et al. 2002b). In vivo, however, the effect of gemfibrozil on the
pharmacokinetics of CYP2C9 substrate drugs has been found to be only minor (Niemi et al.
2001b, Lilja et al. 2005, Niemi et al. 2005a), while it has been shown to greatly increase the
plasma concentrations of several CYP2C8 substrates (Table 8). This discrepancy is possibly
explained by a metabolite of gemfibrozil, gemfibrozil 1-O-?-glucuronide, which is a potent
and selective mechanism-based inhibitor of CYP2C8 (Ogilvie et al. 2006). Further in vivo
evidence for the supposed mechanism-based inhibition of CYP2C8 was provided in study V,
where the gemfibrozil-repaglinide interaction was maintained at least 12 hours after the last
dose of gemfibrozil. However, gemfibrozil and its 1-O-?-glucuronide also inhibit OATP1B1
(Shitara et al. 2004), which could contribute to the gemfibrozil-repaglinide and gemfibrozil-
cerivastatin interactions, as well as explain its effects on drugs that are not metabolised by
CYP enzymes to a significant degree, such as pravastatin and rosuvastatin (Kyrklund et al.
2003, Schneck et al. 2004). Additionally, gemfibrozil has been found to reduce the Clrenal of
pravastatin (Kyrklund et al. 2003), as well as the Clrenal of loperamide and zopiclone-N-oxide
in studies I and II. Recently, gemfibrozil and its metabolites were shown to inhibit the renal
transporter OAT3, providing a possible explanation for the effect of gemfibrozil on the Clrenal
of pravastatin (Nakagomi-Hagihara et al. 2007a).
In this thesis work, using gemfibrozil as a probe inhibitor, the rank order of the importance
of CYP2C8-mediated metabolism in vivo was found to be repaglinide > loperamide >
ibuprofen > zopiclone. The results with loperamide and ibuprofen were in line with previous
in vitro results (Hamman et al. 1997, Kim et al. 2004). Surprisingly, the plasma
concentrations of zopiclone were found not to be affected by gemfibrozil. This is at variance
with earlier in vitro findings, and suggests that the high zopiclone concentrations used in the
earlier in vitro study  led  to  overestimation  of  the  role  of  CYP2C8  in  the  metabolism  of
zopiclone (Becquemont et al. 1999). On the other hand, the role of CYP2C8 in the
metabolism certain other drugs, such as cerivastatin and repaglinide, has apparently been
underestimated on the basis of in vitro experiments (Boberg et al. 1997, Guay 1998).
Whether this underestimation is due to selection of supratherapeutic substrate concentrations
or other experimental issues remains to be elucidated.
The allele frequency of CYP2C8*3 has been reported to be 10-20% in the Caucasian
population (Totah and Rettie 2005). Thus, this quite common polymorphism could be an
important factor determining the inter-individual variability in the pharmacokinetics of drugs
that  are  CYP2C8 substrates.  However,  the  results  of  pharmacogenetic  studies  on  CYP2C8
have been conflicting. In vitro, CYP2C8.3 protein has been found to have decreased activity
to metabolise its substrates (Dai et al. 2001, Bahadur et al. 2002). In vivo, the effect of the
CYP2C8*3 allele seems to be substrate specific, resulting in increased (repaglinide and
rosiglitazone) and decreased (ibuprofen) activity phenotypes, compared to those of the
reference genotype (CYP2C8*1/*1) (Niemi et al. 2003c, Kirchheiner et al. 2006, García-
Martín et al. 2004). However, the results with ibuprofen could be confounded by the fact that
it is metabolised by both CYP2C8 and CYP2C9 (Hamman et al. 1997), and that there is a
linkage disequilibrium between the CYP2C8*3 and CYP2C9*2 variant  alleles  (Yasar  et  al.
2002). On the other hand, another study showed no significant difference in ibuprofen
pharmacokinetics between the heterozygous and homozygous CYP2C9*2 allele carriers and
the subjects with the CYP2C9*1/*1 genotype (Kirchheiner et al. 2002). This contradicts the
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former results, as most of these CYP2C9*2 carriers likely had the same number of
CYP2C8*3 alleles (either homozygous in both or heterozygous in both). The view that the
CYP2C8*3 allele is associated most often with increased metabolic activity in vivo was
supported by the findings of study IV with pioglitazone. However, general conclusions about
all substrates of CYP2C8 can not yet be made, because there may be substrate-specific
effects.
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CONCLUSIONS
Study I
Gemfibrozil, itraconazole, and in particular their combination, raised the plasma
concentrations of loperamide. This indicates that CYP2C8 and CYP3A4 are important in the
elimination of loperamide and that inhibitors of both CYP2C8 and CYP3A4 can increase
loperamide concentrations. Care is warranted if loperamide is used together with drugs that
inhibit both CYP2C8 and CYP3A4 enzymes.
Study II
Gemfibrozil did not increase plasma concentrations or pharmacodynamic effects of
zopiclone, and thus, zopiclone is not significantly metabolised by CYP2C8 in vivo. Although
the concentrations of the active metabolites of zopiclone were moderately affected,
concomitant use of gemfibrozil and zopiclone can be considered safe.
Study III
Gemfibrozil raised the plasma concentrations of R-ibuprofen moderately, but did not affect
those of the active enantiomer S-ibuprofen. Thus, CYP2C8 is only of limited importance in
the metabolism of ibuprofen. The clinical significance of the interaction between gemfibrozil
and ibuprofen is limited, and the inhibition of CYP2C8 is not likely to affect the efficacy or
tolerability of ibuprofen.
Study IV
Trimethoprim moderately raised pioglitazone plasma concentrations. In vitro, the importance
of CYP2C8-mediated metabolism of pioglitazone was high at clinically relevant pioglitazone
concentrations. The CYP2C8*3 allele was associated with decreased plasma concentrations
of  pioglitazone.  Thus,  both  CYP2C8 inhibition  and  pharmacogenetic  factors  can  affect  the
pharmacokinetics of pioglitazone and possibly affect the efficacy and safety of pioglitazone.
Study V
The possibility of a gemfibrozil-repaglinide interaction persisted at least up to 12 hours after
the previous gemfibrozil dose. The main mechanism of the interaction is likely to be
irreversible mechanism-based inhibition of CYP2C8 by gemfibrozil 1-O-?-glucuronide. A
similar long-lasting interaction potential of gemfibrozil with other CYP2C8 substrate drugs
can also be expected.
General conclusions
These studies clarified the role of CYP2C8 in the metabolism and interactions of different
drugs. However, some of the in vivo findings were not directly predictable from previous in
vitro data. Thus, these results emphasise the need for clinical drug interaction studies to
confirm in vitro findings.  The  results  also  confirm  the  role  of  gemfibrozil  as  a  model
inhibitor for CYP2C8 in vivo, and that this interaction potential is long-lasting. Also, genetic
variation can affect the pharmacokinetics of drugs metabolised by CYP2C8, but possible
substrate-specific effects require the use of different substrates.
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